Takayuki Yoshino
#146,207
Most Influential Person Now
Researcher
Takayuki Yoshino's AcademicInfluence.com Rankings
Takayuki Yoshinocomputer-science Degrees
Computer Science
#7349
World Rank
#7740
Historical Rank
Machine Learning
#2682
World Rank
#2717
Historical Rank
Artificial Intelligence
#2976
World Rank
#3022
Historical Rank
Database
#4404
World Rank
#4580
Historical Rank
Download Badge
Computer Science
Takayuki Yoshino's Degrees
- PhD Computer Science University of Tokyo
- Masters Artificial Intelligence Kyoto University
- Bachelors Computer Engineering Osaka University
Similar Degrees You Can Earn
Why Is Takayuki Yoshino Influential?
(Suggest an Edit or Addition)Takayuki Yoshino's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016) (2368)
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial (2013) (2113)
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2012) (965)
- Randomized trial of TAS-102 for refractory metastatic colorectal cancer. (2015) (886)
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer (2019) (846)
- Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. (2020) (802)
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer (2015) (679)
- Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. (2015) (656)
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer (2011) (648)
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. (2019) (620)
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer (2018) (557)
- Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164 (2019) (423)
- Localised Colon Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. (2020) (370)
- Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS (2018) (370)
- Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer. (2018) (368)
- Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. (2015) (281)
- TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. (2012) (279)
- Chromoendoscopy using indigo carmine dye spraying with magnifying observation is the most reliable method for differential diagnosis between non-neoplastic and neoplastic colorectal lesions: a prospective study. (2004) (252)
- Iatrogenic perforation associated with therapeutic colonoscopy: A multicenter study in Japan (2007) (179)
- Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein–Barr virus status in a large cohort of gastric cancer patients (2017) (168)
- A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer. (2017) (168)
- Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study. (2020) (159)
- Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study (2019) (157)
- Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies (2020) (147)
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS (2019) (142)
- Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer (2006) (127)
- Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study (2021) (124)
- Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. (2021) (118)
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS (2019) (117)
- Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer (2019) (112)
- Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC. (2017) (110)
- Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel (2019) (109)
- A new endoscopic tattooing technique for identifying the location of colonic lesions during laparoscopic surgery: a comparison with the conventional technique. (2001) (105)
- Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. (2022) (102)
- Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. (2020) (101)
- Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial. (2018) (99)
- Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients (2015) (95)
- Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations (2014) (94)
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. (2020) (92)
- TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study. (2017) (91)
- Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer (2019) (88)
- Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours (2012) (86)
- Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors (2014) (82)
- Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab (2017) (81)
- Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma (2016) (79)
- [Bevacizumab (Avastin)]. (2007) (78)
- Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study (2017) (78)
- A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer (2015) (77)
- Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies. (2012) (76)
- Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC). (2016) (73)
- Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration. (2017) (71)
- Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer (2019) (67)
- JSCO/ESMO/ASCO/JSMO/TOS: International expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. (2020) (65)
- Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†. (2022) (63)
- 12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE Study. (2016) (62)
- Efficacy of magnifying chromoendoscopy for the differential diagnosis of colorectal lesions (2005) (60)
- Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer. (2016) (60)
- Clinicopathological Study of Early Adenocarcinoma of the Gastric Cardia: Comparison with Early Adenocarcinoma of the Distal Stomach and Esophagus (2001) (59)
- Phase I study of palbociclib, a cyclin‐dependent kinase 4/6 inhibitor, in Japanese patients (2016) (57)
- Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study (2016) (57)
- A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer. (2009) (56)
- Platinum-based Chemotherapy Plus Cetuximab for the First-line Treatment of Japanese Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Results of a Phase II Trial (2013) (56)
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS. (2020) (56)
- 386PEfficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers (2017) (56)
- ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. (2022) (55)
- Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC) (2016) (53)
- Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial (2021) (52)
- Response to Anti-EGFR Therapy in Patients with BRAF non-V600–Mutant Metastatic Colorectal Cancer (2019) (52)
- Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies. (2019) (52)
- Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice. (2019) (52)
- Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study (2015) (51)
- Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. (2021) (51)
- Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912. (2014) (51)
- Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors (2011) (50)
- Synergistic action of Smad4 and Pten in suppressing pancreatic ductal adenocarcinoma formation in mice (2010) (50)
- Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study (2017) (50)
- Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression† (2016) (50)
- Phase I study of the selective BRAFV600inhibitor encorafenib (LGX818) combined with cetuximab and with or without the {alpha}-specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer. (2014) (49)
- Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. (2020) (48)
- Phase II Study of Cetuximab Plus Concomitant Boost Radiotherapy in Japanese Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck (2013) (48)
- KRAS mutations detected by the amplification refractory mutation system–Scorpion assays strongly correlate with therapeutic effect of cetuximab (2011) (47)
- Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies (2019) (46)
- A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer (2019) (46)
- BEACON CRC study safety lead-in (SLI) in patients with BRAFV600E metastatic colorectal cancer (mCRC): Efficacy and tumor markers. (2018) (44)
- CIRCULATE‐Japan: Circulating tumor DNA–guided adaptive platform trials to refine adjuvant therapy for colorectal cancer (2021) (44)
- Evolving role of regorafenib for the treatment of advanced cancers. (2020) (44)
- Simultaneous identification of 36 mutations in KRAS codons 61and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit (2013) (44)
- Immunohistochemical Evaluation of a Malignant Intestinal Carcinoid in a Dog (2003) (41)
- Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer (2018) (41)
- Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE—a global phase III study (2018) (40)
- Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer (2021) (40)
- Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC) (2012) (40)
- Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients11 (2015) (39)
- Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer. (2018) (39)
- [Breast cancer in the early stage]. (2012) (39)
- Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein–Barr virus status, and cancer genome alterations in metastatic gastric cancer (2018) (38)
- KRAS mutational status in Japanese patients with colorectal cancer: results from a nationwide, multicenter, cross-sectional study. (2013) (38)
- Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC). (2020) (38)
- Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC). (2020) (38)
- A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01. (2020) (38)
- Localized Amyloidosis in Canine Mammary Tumors (2000) (38)
- Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study (2018) (38)
- A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First‐line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study (2018) (37)
- Systemic atherosclerosis in dogs: histopathological and immunohistochemical studies of atherosclerotic lesions. (1998) (36)
- Real‐world data on microsatellite instability status in various unresectable or metastatic solid tumors (2021) (36)
- LBA-5 ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer (2020) (36)
- Clinical practice guidance for next‐generation sequencing in cancer diagnosis and treatment (Edition 1.0) (2018) (36)
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2016 for the Clinical Practice of Hereditary Colorectal Cancer (Translated Version) (2018) (36)
- The Impact of Molecular Subtype on Efficacy of Chemotherapy and Checkpoint Inhibition in Advanced Gastric Cancer (2020) (35)
- KEYNOTE-177: Phase III randomized study of pembrolizumab versus chemotherapy for microsatellite instability-high advanced colorectal cancer. (2021) (35)
- Clinical features of interstitial lung disease induced by standard chemotherapy (FOLFOX or FOLFIRI) for colorectal cancer. (2010) (35)
- KEYNOTE-177: Phase 3, open-label, randomized study of first-line pembrolizumab (Pembro) versus investigator-choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC). (2018) (35)
- TRIUMPH: Primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): A GOZILA sub-study (2019) (35)
- Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC). (2019) (34)
- A Low Tumor Mutational Burden and PTEN Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H/dMMR Gastrointestinal Tumors (2021) (34)
- Time profile of adverse events (AEs) from regorafenib (REG) treatment for metastatic colorectal cancer (mCRC) in the phase III CORRECT study. (2013) (33)
- Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia. (2011) (33)
- Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1) (2020) (32)
- REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients (2019) (32)
- Large-Scale, Prospective Observational Study of Regorafenib in Japanese Patients with Metastatic Colorectal Cancer in a Real-World Clinical Setting. (2019) (31)
- Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials (2020) (30)
- A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors (2016) (30)
- The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer? (2018) (29)
- Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). (2021) (28)
- Pembrolizumab in microsatellite instability high cancers: Updated analysis of the phase II KEYNOTE-164 and KEYNOTE-158 studies (2019) (28)
- KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer (2012) (28)
- Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors (2014) (28)
- Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors (2012) (28)
- Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial) (2020) (28)
- Utility of the quasi‐monomorphic variation range in unresectable metastatic colorectal cancer patients (2018) (27)
- Prognostic significance of tumor regression grade for patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery (2016) (27)
- KEYNOTE-177: Randomized phase III study of pembrolizumab versus investigator-choice chemotherapy for mismatch repair-deficient or microsatellite instability-high metastatic colorectal carcinoma. (2017) (27)
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS. (2020) (27)
- TAS-102 Safety in Metastatic Colorectal Cancer: Results From the First Postmarketing Surveillance Study. (2016) (26)
- A MULTICENTER RANDOMIZED CONTROLLED TRIAL DESIGNED TO EVALUATE FOLLOW‐UP SURVEILLANCE STRATEGIES FOR COLORECTAL CANCER: THE JAPAN POLYP STUDY (2004) (26)
- Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors (2015) (26)
- KEYNOTE-164: Phase 2 study of pembrolizumab for patients with previously treated, microsatellite instability-high advanced colorectal carcinoma. (2016) (26)
- Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial) (2015) (25)
- Impact of hemoglobin level on survival in definitive chemoradiotherapy for T4/M1 lymph node esophageal cancer. (2008) (25)
- Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer (2015) (25)
- Amrubicin for the treatment of neuroendocrine carcinoma of the gastrointestinal tract: a retrospective analysis of five cases (2011) (25)
- FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study (2014) (24)
- Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer (2013) (24)
- Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers (2018) (24)
- Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for RAS Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study (2021) (24)
- BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E-mutant metastatic colorectal cancer. (2019) (24)
- Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer (2013) (24)
- Safety and Pharmacokinetics of Second-line Ramucirumab plus FOLFIRI in Japanese Patients with Metastatic Colorectal Carcinoma. (2015) (24)
- A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer (2012) (23)
- Distribution and prevalence of colorectal hyperplastic polyps using magnifying pan‐mucosal chromoendoscopy and its relationship with synchronous colorectal cancer: Prospective study (2005) (23)
- Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial). (2015) (23)
- Histopathological and immunohistochemical analysis of the endocrine and exocrine pancreas in twelve cattle with insulin-dependent diabetes mellitus (IDDM). (1999) (23)
- Panitumumab in Japanese Patients with Unresectable Colorectal Cancer: A Post-marketing Surveillance Study of 3085 Patients† (2014) (23)
- Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial (2017) (22)
- Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability–High Locally Advanced Rectal Cancer (2022) (22)
- Targeting of super-enhancers and mutant BRAF can suppress growth of BRAF-mutant colon cancer cells via repression of MAPK signaling pathway. (2017) (22)
- LBA-07Updated Results of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC) (2015) (22)
- Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01). (2021) (22)
- Combination chemotherapy with irinotecan and cisplatin in pretreated patients with unresectable or recurrent gastric cancer (2006) (22)
- Phase II trial of aflibercept with FOLFIRI as a second‐line treatment for Japanese patients with metastatic colorectal cancer (2019) (22)
- BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer (2020) (21)
- Phase Ib/II Study of Biweekly TAS‐102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study) (2020) (21)
- Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors (2012) (21)
- Short-term results of VOLTAGE-A: Nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer. (2020) (21)
- Pulmonary tumor thrombotic microangiopathy associated with esophageal squamous cell carcinoma. (2011) (21)
- Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial. (2017) (21)
- Clinical Validation of Newly Developed Multiplex Kit Using Luminex xMAP Technology for Detecting Simultaneous RAS and BRAF Mutations in Colorectal Cancer: Results of the RASKET-B Study1 (2018) (20)
- Biased discordance of KRAS mutation detection in archived colorectal cancer specimens between the ARMS-Scorpion method and direct sequencing. (2011) (20)
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. (2021) (20)
- Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database. (2020) (20)
- Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer (2018) (20)
- Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer (2019) (20)
- Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution. (2016) (20)
- Sleep Disturbance Worsens Lower Urinary Tract Symptoms: The Nagahama Study. (2019) (20)
- A Pleomorphic Adenoma of the Lacrimal Gland in a Dog (2000) (19)
- Predictors for Early Recurrence After Hepatectomy for Initially Unresectable Colorectal Liver Metastasis (2013) (19)
- Regorafenib (REG) in progressive metastatic colorectal cancer (mCRC): Analysis of age subgroups in the phase III CORRECT trial. (2013) (19)
- TAS-102 versus placebo plus best supportive care in patients with metastatic colorectal cancer refractory to standard therapies: Final survival results of the phase III RECOURSE trial. (2016) (19)
- Feasibility and robustness of amplification refractory mutation system (ARMS)-based KRAS testing using clinically available formalin-fixed, paraffin-embedded samples of colorectal cancers. (2011) (19)
- RAS Mutations in Circulating Tumor DNA and Clinical Outcomes of Rechallenge Treatment With Anti-EGFR Antibodies in Patients With Metastatic Colorectal Cancer (2020) (19)
- Genetic polymorphisms of FCGRT encoding FcRn in a Japanese population and their functional analysis. (2010) (19)
- Immunohistochemical Evaluation of a Malignant Pheochromocytoma in a Wolfdog (2001) (18)
- Oxaliplatin-Based Adjuvant Chemotherapy Duration (3 vs. 6 Months) for High-Risk Stage II Colon Cancer: The Randomized Phase 3 ACHIEVE-2 Trial. (2020) (18)
- Cyclooxygenase-2 is overexpressed in serrated adenoma of the colorectum (2001) (18)
- Clinical outcome of Japanese metastatic colorectal cancer patients harbouring the KRAS p.G13D mutation treated with cetuximab + irinotecan. (2012) (18)
- A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors (2013) (18)
- Rationale and Design for the LUME-Colon 1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Nintedanib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Colorectal Cancer Refractory to Standard Treatment. (2016) (17)
- Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone. (2021) (17)
- Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer (2020) (17)
- Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin (2021) (17)
- International Harmonization of Provisional Diagnostic Criteria for ERBB2-Amplified Metastatic Colorectal Cancer Allowing for Screening by Next-Generation Sequencing Panel (2020) (17)
- Time course of regorafenib-associated adverse events in the phase III CORRECT study. (2013) (17)
- Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, Third Edition (2018) (17)
- Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy (2019) (17)
- Results of a Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial (CORRECT) of Regorafenib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients with Metastatic Colorectal Cancer (MCRC) who have Progressed after Standard Therapies (2012) (17)
- Effect of food on the pharmacokinetics of TAS‐102 and its efficacy and safety in patients with advanced solid tumors (2016) (17)
- Survival Outcomes of Resected BRAF V600E Mutant Colorectal Liver Metastases: A Multicenter Retrospective Cohort Study in Japan (2020) (17)
- Phase 3 RECOURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: Geographic subgroups. (2015) (16)
- The initial assessment of expert panel performance in core hospitals for cancer genomic medicine in Japan (2021) (16)
- Exposure–response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial (2017) (16)
- Relationship between the immune microenvironment of different locations in a primary tumour and clinical outcomes of oesophageal squamous cell carcinoma (2019) (16)
- Prophylactic Use of Oral Dexamethasone to Alleviate Fatigue During Regorafenib Treatment for Patients With Metastatic Colorectal Cancer (2017) (16)
- BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC). (2021) (16)
- Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors (2020) (16)
- Adenocarcinoma in Solitary Large Hyperplastic Polyp Diagnosed by Magnifying Colonoscope (2002) (16)
- Induction chemotherapy with docetaxel, cisplatin and S-1 followed by proton beam therapy concurrent with cisplatin in patients with T4b nasal and sinonasal malignancies. (2012) (16)
- SCRUM‐Japan GI‐SCREEN and MONSTAR‐SCREEN: Path to the realization of biomarker‐guided precision oncology in advanced solid tumors (2021) (16)
- A new prognostic and predictive tool for shared decision making in stage III colon cancer. (2020) (16)
- A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites (2018) (16)
- Development of RNA-FISH Assay for Detection of Oncogenic FGFR3-TACC3 Fusion Genes in FFPE Samples (2016) (16)
- Large-scale comprehensive immunohistochemical biomarker analyses in esophageal squamous cell carcinoma (2017) (15)
- Effect of RECIST revision on classification of target lesions and overall response in advanced gastric cancer patients (2013) (15)
- Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data set (2018) (15)
- O-10 ANCHOR CRC: Results from a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E–mutant metastatic colorectal cancer (2021) (15)
- Phospholipase D2 promotes disease progression of renal cell carcinoma through the induction of angiogenin (2018) (15)
- REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer (2021) (15)
- Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC). (2019) (15)
- Onset of neutropenia as an indicator of treatment response in the phase 3 RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo in patients with metastatic colorectal cancer. (2017) (14)
- Impact of Preoperative Circulating Tumor DNA Status on Survival Outcomes After Hepatectomy for Resectable Colorectal Liver Metastases (2021) (14)
- Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503. (2018) (14)
- Genetic polymorphisms of copper- and platinum drug-efflux transporters ATP7A and ATP7B in Japanese cancer patients. (2009) (14)
- REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients. (2019) (14)
- Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition (2019) (14)
- [High-throughput screening method of KRAS mutations at codons 12 and 13 in formalin-fixed paraffin-embedded tissue specimens of metastatic colorectal cancer]. (2011) (14)
- Time course of regorafenib-associated adverse events in the phase III CORRECT study (2013) (14)
- CanStem303C trial: A phase III study of napabucasin (BBI-608) in combination with 5-fluorouracil (5-FU), leucovorin, irinotecan (FOLFIRI) in adult patients with previously treated metastatic colorectal cancer (mCRC). (2017) (14)
- LBA-08Results of a phase 1b study of the selective BRAF V600 inhibitor encorafenib in combination with cetuximab alone or cetuximab + alpelisib for treatment of patients with advanced BRAF-mutant metastatic colorectal cancer (2015) (14)
- Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan. (2007) (14)
- Impact of Nocturia on Mortality: The Nagahama Study. (2020) (14)
- 5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study (2015) (14)
- O-0022RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE III STUDY OF TAS-102 VS. PLACEBO, WITH BEST SUPPORTIVE CARE (BSC), IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) REFRACTORY TO STANDARD THERAPIES (RECOURSE) (2014) (14)
- BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib + MEK inhibitor binimetinib + anti-epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer. (2018) (14)
- Impact of Circulating Tumor DNA–Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors (2022) (14)
- A novel endoscopic device for retrieval of polyps resected from the colon and rectum. (2004) (13)
- A phase I escalating single-dose and weekly fixed-dose study of cetuximab pharmacokinetics in Japanese patients with solid tumors (2009) (13)
- The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study. (2021) (13)
- Longitudinal Analysis of Bidirectional Relationships Between Nocturia and Depressive Symptoms: The Nagahama Study. (2019) (13)
- FOLFIRI Plus Bevacizumab 5 mg/kg Versus 10 mg/kg as Second-line Therapy in Patients with Metastatic Colorectal Cancer Who Have Failed First-line Bevacizumab Plus Oxaliplatin-based Therapy: A Randomized Phase III Study (EAGLE Study) (2011) (13)
- Immunohistochemical analysis of equine pulmonary granular cell tumours. (2001) (13)
- Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial). (2016) (13)
- Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer: A Review. (2022) (13)
- Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors (2015) (13)
- REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan—Biomarker analysis. (2018) (13)
- Retrospective analysis of S-1 monotherapy in patients with metastatic colorectal cancer after failure to fluoropyrimidine and irinotecan or to fluoropyrimidine, irinotecan and oxaliplatin. (2009) (12)
- Rationale and design of the TRUSTY study: a randomised, multicentre, open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan, fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following fi (2018) (12)
- 11LBA Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF mutant colorectal cancer (2014) (12)
- Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1. (2020) (12)
- Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. (2020) (12)
- MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma—Trial in Progress. (2021) (12)
- Phase 1 study of OCV‐C02, a peptide vaccine consisting of two peptide epitopes for refractory metastatic colorectal cancer (2017) (12)
- An investigator initiated multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE). (2015) (12)
- Impact of DNA integrity on the success rate of tissue‐based next‐generation sequencing: Lessons from nationwide cancer genome screening project SCRUM‐Japan GI‐SCREEN (2020) (12)
- Management of ureteral obstruction in advanced testicular tumor with lymph node metastasis. (2012) (12)
- Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. (2021) (12)
- TAS-102 versus placebo (PBO) in patients (pts) ≥65 years (y) with metastatic colorectal cancer (mCRC): An age-based analysis of the recourse trial. (2015) (12)
- Enhanced tumor response to radiotherapy after PD-1 blockade in metastatic gastric cancer (2020) (12)
- A retrospective study of second-line chemotherapy for unresectable or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus platinum (2008) (12)
- An international consortium study in chemorefractory metastatic colorectal cancer (mCRC) patients (pts) to assess the impact of FCGR polymorphisms on cetuximab efficacy. (2011) (11)
- Analysis of plasma protein biomarkers from the CORRECT phase III study of regorafenib for metastatic colorectal cancer. (2013) (11)
- JOIN trial: treatment outcome and recovery status of peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer (2019) (11)
- Prognostic Value and Molecular Landscape of HER2 Low-Expressing Metastatic Colorectal Cancer. (2020) (11)
- A randomized phase III study of napabucasin [BBI608] (NAPA) vs placebo (PBO) in patients (pts) with pretreated advanced colorectal cancer (ACRC): the CCTG/AGITG CO.23 trial (2016) (11)
- The liposome of trehalose dimycolate extracted from M. bovis BCG induces antitumor immunity via the activation of dendritic cells and CD8+ T cells (2021) (11)
- VOLTAGE: Investigator-initiated clinical trial of nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable locally advanced rectal cancer. (2019) (11)
- Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Anti–PD-1 Therapy (2022) (11)
- Onset of neutropenia as an indicator of treatment response in the randomized phase II of TAS-102 vs placebo in Japanese patients with metastatic colorectal cancer (Study J003-10040030). (2016) (10)
- Multicenter phase II study of trastuzumab deruxtecan (DS-8201) for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial. (2020) (10)
- Early colon cancers detected by FDG-pet: a report of two cases with immunohistochemical investigation. (2004) (10)
- Small cell carcinoma of the esophagus responding to fourth-line chemotherapy with weekly paclitaxel (2005) (10)
- Safety and efficacy of regorafenib post-marketing surveillance (PMS) in Japanese patients with metastatic colorectal cancer (mCRC). (2017) (10)
- Phase I trial of combination chemotherapy with docetaxel, cisplatin and S-1 (TPS) in patients with locally advanced or recurrent/metastatic head and neck cancer. (2011) (10)
- Nationwide large-scale investigation of microsatellite instability status in more than 18,000 patients with various advanced solid cancers. (2020) (10)
- Integrated safety summary for trifluridine/tipiracil (TAS-102) (2018) (10)
- LBA24Efficacy of 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer (CC): Results from phase III ACHIEVE trial as part of the International Duration Evaluation of Adjuvant therapy (IDEA) Collaboration (2017) (10)
- BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer (2020) (10)
- Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy‐naïve Patients With RAS (KRAS/NRAS) Wild‐type, Metastatic Colorectal Cancer (2017) (10)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
- BRAF V600E Mutation in First-line Metastatic Colorectal Cancer: an Analysis of Individual Patient Data from the ARCAD Database. (2021) (10)
- Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials (2018) (10)
- Eimeria Organisms Develop in the Epithelial Cells of Equine Small Intestine (2002) (10)
- Adenocarcinoma in solitary large hyperplastic polyp diagnosed by magnifying colonoscope: report of a case. (2002) (10)
- Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer (2021) (9)
- Effects of Metastatic Sites on Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer (2022) (9)
- Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer. (2008) (9)
- The Mechanism of Action of Regorafenib in Colorectal Cancer: A Guide for the Community Physician. (2019) (9)
- Emergence of Concurrent Multiple EGFR Mutations and MET Amplification in a Patient With EGFR-Amplified Advanced Gastric Cancer Treated With Cetuximab. (2020) (9)
- ANCHOR CRC: a phase 2, open-label, single arm, multicenter study of encorafenib (ENCO), binimetinib (BINI), plus cetuximab (CETUX) in patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer (mCRC). (2019) (9)
- 396O Health-related quality of life (HRQoL) in patients (pts) treated with pembrolizumab (pembro) vs chemotherapy as first-line treatment in microsatellite instability-high (MSI-H) and/or deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Phase III KEYNOTE-177 study (2020) (9)
- 517PBEACON CRC: safety lead-in (SLI) for the combination of binimetinib (BINI), encorafenib (ENCO), and cetuximab (CTX) in patients (pts) with BRAF-V600E metastatic colorectal cancer (mCRC) (2017) (9)
- LBA13PHASE III RECOURSE TRIAL OF TAS-102 VS. PLACEBO, WITH BEST SUPPORTIVE CARE (BSC), IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) REFRACTORY TO STANDARD THERAPIES (2014) (9)
- A randomized, phase IIb study of sunitinib plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) versus bevacizumab plus mFOLFOX6 as first-line treatment for metastatic colorectal cancer (mCRC): Interim results. (2010) (9)
- A case of acute adrenal insufficiency unmasked during sunitinib treatment for metastatic renal cell carcinoma. (2012) (8)
- The nationwide cancer genome screening project in Japan, SCRUM Japan GISCREEN: Efficient identification of cancer genome alterations in advanced biliary tract cancer. (2017) (8)
- Large-scale analyses of tumor mutation burdens (TMBs) across various advanced gastrointestinal (GI) malignancies in the nationwide cancer genome screening project, SCRUM-Japan GI-SCREEN. (2018) (8)
- Serum HER2 levels and HER2 status in tumor cells in advanced gastric cancer patients. (2015) (8)
- Abstract CT136: Final biomarker analysis of the phase I study of the selective BRAF V600 inhibitor encorafenib (LGX818) combined with cetuximab with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF-mutant colorectal cancer (2015) (8)
- Characteristics of patients (pts) with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) who had progression-free survival (PFS) >4 months (m): Subgroup analysis of the phase 3 CORRECT trial (2016) (8)
- Tumor KRAS status predicts responsiveness to panitumumab in Japanese patients with metastatic colorectal cancer. (2011) (8)
- Onset of neutropenia as an indicator of treatment response in the phase III RECOURSE trial of TAS-102 vs placebo in patients with metastatic colorectal cancer. (2016) (8)
- Impact of a metastatic site on circulating tumor DNA (ctDNA) analysis in patients (pts) with metastatic colorectal cancer (mCRC). (2021) (8)
- Updated results of phase I study of trastuzumab deruxtecan (DS-8201a) in HER2-expressing advanced colorectal cancer. (2018) (8)
- 612TiPTRIUMPH Study: A multicenter Phase II study to evaluate efficacy and safety of combination therapy with trastuzumab and pertuzumab in patients with HER2-positive metastatic colorectal cancer (EPOC1602) (2017) (8)
- Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02). (2021) (8)
- O-11 Monitoring molecular residual disease by circulating tumor DNA in resectable colorectal cancer: Molecular subgroup analyses of a prospective observational study GALAXY in CIRCULATE-Japan (2021) (8)
- Pertuzumab plus trastuzumab and real-world standard of care (SOC) for patients (pts) with treatment refractory metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) confirmed by tumor tissue or ctDNA analysis (TRIUMPH, EPOC1602). (2021) (8)
- Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer (2020) (8)
- PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer. (2016) (8)
- The Japanese Society of Pathology Practical Guidelines on the handling of pathological tissue samples for cancer genomic medicine (2021) (8)
- The nationwide cancer genome screening project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced pancreatic cancer. (2018) (7)
- Re-evaluating disease-free survival (DFS) as an endpoint versus overall survival (OS) in adjuvant colon cancer (CC) trials with chemotherapy +/- biologics: An updated surrogacy analysis based on 18,886 patients (pts) from the Accent database. (2019) (7)
- Pembrolizumab monotherapy for patients with advanced MSI-H colorectal cancer: Longer-term follow-up of the phase II, KEYNOTE-164 study. (2020) (7)
- Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer: A Narrative Review. (2022) (7)
- Phase I dose escalation and pharmacokinetics study of intravenous aflibercept plus irinotecan, 5-fluorouracil, and folinic acid (FOLFIRI) in patients with metastatic colorectal cancer. (2011) (7)
- Genetic polymorphisms of FCGR2A encoding Fcγ receptor IIa in a Japanese population and functional analysis of the L273P variant (2012) (7)
- Application of a Combination of a Knowledge-Based Algorithm and 2-Stage Screening to Hypothesis-Free Genomic Data on Irinotecan-Treated Patients for Identification of a Candidate Single Nucleotide Polymorphism Related to an Adverse Effect (2014) (7)
- Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer (2019) (7)
- Phase 3, open-label, randomized study of first-line pembrolizumab (pembro) vs investigator-choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC): KEYNOTE-177. (2017) (7)
- Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mutant metastatic colorectal cancer: Expanded results from a randomized, 3-arm, phase III study vs the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC) (2019) (7)
- Cationized liposomal keto-mycolic acids isolated from Mycobacterium bovis bacillus Calmette-Guérin induce antitumor immunity in a syngeneic murine bladder cancer model (2019) (7)
- Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab. (2010) (7)
- Efficacy and safety of ramucirumab-containing chemotherapy in patients with pretreated metastatic gastric neuroendocrine carcinoma (2018) (7)
- Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial. (2022) (7)
- Construction of possible integrated predictive index based on EGFR and ANXA3 polymorphisms for chemotherapy response in fluoropyrimidine-treated Japanese gastric cancer patients using a bioinformatic method (2015) (7)
- The Nationwide Cancer Genome Screening Project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced colorectal cancer. (2017) (7)
- Identification of a candidate single-nucleotide polymorphism related to chemotherapeutic response through a combination of knowledge-based algorithm and hypothesis-free genomic data. (2013) (7)
- P-120 Prospective observational study monitoring circulating tumor DNA in resectable colorectal cancer patients undergoing radical surgery: GALAXY study in CIRCULATE-Japan (trial in progress) (2020) (7)
- Efficacy and Safety of Carboplatin Plus Paclitaxel as the First-, Second-, and Third-line Chemotherapy in Men With Castration-resistant Prostate Cancer. (2019) (7)
- Incidence and localization of lymphoid follicles in early colorectal neoplasms. (2005) (7)
- PD-0034POPULATION PHARMACOKINETICS ANALYSIS OF REGORAFENIB AND ITS ACTIVE METABOLITES FROM THE PHASE III CORRECT STUDY OF METASTATIC COLORECTAL CANCER (2013) (7)
- Supportive treatment for hematologic toxicities in the phase 3 RECOURSE trial of TAS-102 vs placebo with best supportive care in patients with metastatic colorectal cancer. (2016) (7)
- 386O Exploratory biomarker analysis of DESTINY-CRC01, a phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd, DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC) (2021) (7)
- Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer (2023) (7)
- APOLLON: A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC). (2018) (7)
- REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan: Quality of life analysis. (2018) (7)
- Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. (2021) (6)
- Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study (2021) (6)
- A phase I study of BBI608, a cancer stemness inhibitor, administered with paclitaxel (PTX) as combination therapy (Rx) for pretreated unresectable or recurrent gastric cancer. (2015) (6)
- Mutational analysis of biomarker samples from the CORRECT study: Correlating mutation status with clinical response to regorafenib. (2013) (6)
- PD-014Final survival results and onset of neutropenia as an indicator of therapeutic effect in phase 2 of TAS-102 vs placebo with metastatic colorectal cancer (J003-10040030) (2016) (6)
- Genetic variation and haplotype structures of the glutathione S-transferase genes GSTA1 and GSTA2 in Japanese colorectal cancer patients. (2011) (6)
- SO-37 Short-term results of VOLTAGE-A: Nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stability and microsatellite instability-high, locally advanced rectal cancer (EPOC 1504) (2020) (6)
- Gastrointestinal Perforation and Fistula Formation in 5 Patients With Colorectal Cancer During Treatment With Regorafenib (2017) (6)
- Are BRAF mutated metastatic colorectal cancer (mCRC) tumors more responsive to VEGFR-2 blockage? Analysis of patient outcomes by RAS/RAF mutation status in the RAISE study—A global, randomized, double-blind, phase III study. (2018) (6)
- Activity of S-1 in advanced or recurrent gastric cancer patients after failure of prior chemotherapy, including irinotecan + cisplatin or fluorouracil (except S-1). (2009) (6)
- Clinical impact of baseline renal function on safety and early discontinuation of adjuvant capecitabine plus oxaliplatin in elderly patients with resected colon cancer: a multicenter post-marketing surveillance study. (2019) (6)
- LacdiNAc-Glycosylated Prostate-specific Antigen Density is a Potential Biomarker of Prostate Cancer. (2019) (6)
- Phase I study of sunitinib plus modified FOLFOX6 in Japanese patients with treatment-naive colorectal cancer. (2012) (6)
- CanStem303C trial: A phase III study of BBI-608 (napabucasin) in combination with 5-fluorouracil (5-FU), leucovorin, irinotecan (FOLFIRI) in adult patients with previously treated metastatic colorectal cancer (mCRC) (2016) (6)
- HER2-targeted therapy should be shifted towards an earlier line for patients with anti-EGFR-therapy naïve, HER2-amplified metastatic colorectal cancer (2019) (6)
- The Moment that KRAS Mutation Started to Evolve into Precision Medicine in Metastatic Colorectal Cancer. (2016) (6)
- The NCIC CTG and AGITG CO.23 trial: A phase III randomized study of BBI608 plus best supportive care (BSC) versus placebo (PBO) plus BSC in patients (Pts) with pretreated advanced colorectal carcinoma (CRC). (2014) (6)
- PARADIGM study: A multicenter, randomized, phase III study of 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer. (2016) (6)
- gastrointestinal tumours, colorectalNintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Results of the phase III LUME-colon 1 study (2016) (6)
- Histopathological factors affecting the extraction of high quality genomic DNA from tissue sections for next-generation sequencing. (2019) (6)
- Clinical outcome in patients with metastatic colorectal cancer harboring KRAS p.G13D mutation treated with cetuximab. (2011) (6)
- Drug-exposed cancer-associated fibroblasts facilitate gastric cancer cell progression following chemotherapy (2021) (6)
- Genomic immunotherapy (IO) biomarkers detected on comprehensive genomic profiling (CGP) of tissue and circulating tumor DNA (ctDNA). (2021) (5)
- Molecular prognostic markers in advanced gastric cancer: Correlative study in the Japan Clinical Oncology Group trial JCOG9912. (2011) (5)
- Phase 3 Correct Trial of Regorafenib in Metastatic Colorectal Cancer (MCRC): Overall Survival Update (2012) (5)
- Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7 (2021) (5)
- LBA25 FRESCO-2: A global phase III multiregional clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer (2022) (5)
- E13Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the CORRECT trial who had progression-free survival (PFS) longer than 4 months (2015) (5)
- Mutational analysis of biomarker samples from the CORRECT study: Correlating mutation status with clinical response to regorafenib (2013) (5)
- Overall survival (OS) with encorafenib (enco) + cetuximab (cetux) in BEACON CRC: Effect of prior therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC). (2021) (5)
- TP53 codon 72 polymorphism is associated with FGFR3 and RAS mutation in non-muscle-invasive bladder cancer (2019) (5)
- Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer (2020) (5)
- ICGC-ARGO precision medicine: familial matters in pancreatic cancer. (2022) (5)
- Novel Immunological Approaches in the Treatment of Locally Advanced Rectal Cancer. (2021) (5)
- The nationwide genomic screening project for gastrointestinal cancer in Japan (GI-SCREEN): Simultaneous identification of KRAS, NRAS, BRAF, and PIK3CA mutation in advanced colorectal cancer (aCRC) (GI-SCREEN 2013-01). (2015) (5)
- Atypical RAS Mutations in Metastatic Colorectal Cancer. (2019) (5)
- KEYNOTE-177: First-line, open-label, randomized, phase III study of pembrolizumab (MK-3475) versus investigator-choice chemotherapy for mismatch repair deficient or microsatellite instability-high metastatic colorectal carcinoma. (2016) (5)
- A phase I study of the chimeric monoclonal anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a single agent in subjects from Japan with advanced solid tumors: Safety, pharmacokinetics (PK) (2005) (5)
- Molecular correlates of clinical benefit in previously treated patients (pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC) from the BEACON study. (2021) (5)
- A Proposal for Progression-Free Survival Assessment in Patients with Early Progressive Cancer. (2017) (5)
- Effect of age, gender, and performance status (PS) on the duration results of adjuvant chemotherapy for stage III colon cancer: The IDEA collaboration. (2018) (5)
- International harmonization of diagnostic criteria for HER2-amplified metastatic colorectal cancer and application of targeted next-generation sequencing panel as a diagnostic method. (2018) (5)
- A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer (2015) (5)
- Scoop: Multicenter phase I/II trial of BBI608 and pembrolizumab in patients with metastatic colorectal cancer (EPOC1503). (2020) (4)
- Effect of thymidine kinase 1 expression on prognosis and treatment outcomes in refractory metastatic colorectal cancer: Results from two randomized studies of TAS-102 versus a placebo. (2017) (4)
- VOLTAGE: Multicenter phase Ib/II study of nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy (CRT) with capecitabine in patients with locally advanced rectal cancer (LARC). (2018) (4)
- FMS‐like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer (2020) (4)
- Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial (2022) (4)
- Prognostic value of neutrophil-to-lymphocyte ratio (NLR) on overall survival (OS), progression free survival (PFS) and disease control rate (DCR) in patients with metastatic colorectal cancer (mCRC) from the RECOURSE study. (2018) (4)
- Therapeutic landscape and future direction of metastatic colorectal cancer (2023) (4)
- LBA21_PRProspective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): Updated results of IDEA (International Duration Evaluation of Adjuvant chemotherapy) (2017) (4)
- RAS mutations in circulating tumor DNA (ctDNA) and clinical outcomes of rechallenge treatments with anti-EGFR antibodies in patients with metastatic colorectal cancer (mCRC). (2019) (4)
- Open-label phase II/III study of nivolumab plus standard of care versus standard of care for first-line treatment of metastatic colorectal cancer: Checkmate-9X8. (2019) (4)
- Phase I study of napabucasin in combination with FOLFIRI + bevacizumab in Japanese patients with metastatic colorectal cancer (2021) (4)
- Medical history of nocturnal enuresis during school age is an independent risk factor for nocturia in adults: The Nagahama study (2020) (4)
- Results of a retrospective analysis of gemcitabine as a second-line treatment after chemoradiotherapy and maintenance chemotherapy using 5-fluorouracil in patients with locally advanced pancreatic cancer (2008) (4)
- Colonic perforation after endoscopic biopsy of a submucosal tumor: successful conservative treatment (2002) (4)
- ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer. (2023) (4)
- Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses. (2019) (4)
- Clinicopathological features of patients with colorectal cancer among KRAS wild type p.G13D and other mutations: Results from a multicenter, cross-sectional study by the Japan Study Group of KRAS Mutation in Colorectal Cancer. (2011) (4)
- Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy (2022) (4)
- Phase I clinical and pharmacokinetic study of S-1 plus oral leucovorin in patients with metastatic colorectal cancer (2016) (4)
- Phase I dose-finding study of golvatinib (E7050), a c-Met and Eph receptor targeted multi-kinase inhibitor, administered orally BID to patients with advanced solid tumors. (2012) (4)
- Sustainable Clinical Development of Adjuvant Chemotherapy for Colon Cancer (2021) (4)
- Landscape of genomic alterations of circulating tumor DNA in advanced genitourinary cancer patients: SCRUM-Japan MONSTAR SCREEN Project. (2021) (4)
- A basket trial of trastuzumab deruxtecan, a HER2-targeted antibody-drug conjugate, for HER2-amplified solid tumors identified by circulating tumor DNA analysis (HERALD trial). (2020) (4)
- Possible risk of overestimation of renal function using cystatin C-based eGFR in testicular cancer survivors treated with cisplatin-based chemotherapy (2018) (4)
- Re-Evaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials. (2021) (4)
- Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors. (2022) (4)
- LBA26 BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy (chemo) for BRAFV600E metastatic colorectal cancer (mCRC) (2022) (4)
- Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials (2022) (4)
- Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer (2020) (4)
- Phase II study of S-1, oral leucovorin, oxaliplatin, and bevacizumab combination therapy (SOL+BV; SOLA) in patients with unresectable metastatic colorectal cancer (mCRC). (2012) (4)
- Utility of circulating tumor DNA (ctDNA) versus tumor tissue clinical sequencing for enrolling patients (Pts) with advanced gastrointestinal (GI) cancer to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA Combined Analysis. (2020) (4)
- Clinical impact of expanded BRAF mutational status on the outcome for metastatic colorectal cancer patients with anti-EGFR antibody: An analysis of the BREAC trial (Biomarker Research for Anti-EGFR Monoclonal Antibodies by Comprehensive Cancer Genomics). (2015) (4)
- PD-025RECOURSE trial: impact of adverse events on quality of life and duration of TAS-102 (trifluridine and tipiracil) treatment (2016) (4)
- A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors (2016) (4)
- Non-surgical treatment for localized gastric mucosa-associated lymphoid tissue (MALT) lymphoma: Preliminary results of a multicenter prospective study in Japan (2004) (4)
- Post-marketing surveillance study of trifluridine/tipiracil in patients with metastatic colorectal cancer. (2021) (4)
- Correction: A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer (2020) (3)
- Impact of the 12-gene recurrence score assay on deciding adjuvant chemotherapy for stage II and IIIA/B colon cancer: the SUNRISE-DI study (2021) (3)
- [Clinical development of biomarkers for personalized medicine]. (2010) (3)
- Clinicopathological, endoscopic, and molecular characteristics of the “skirt” – a new entity of lesions at the margin of laterally spreading tumors (2016) (3)
- Utility of circulating tumor DNA (ctDNA) versus tumor tissue clinical sequencing for enrolling patients (pts) with advanced non-colorectal (non-CRC) gastrointestinal (GI) cancer to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA combined analysis. (2020) (3)
- 6099 POSTER The Value of Thymidine Kinase 1 (TK1) and Thymidine Phosphorylase (TP) Expression as Predictive Factors With the Treatment Efficacy of TAS-102, a Novel Antitumour Agent, in Patients (pts) With Metastatic Colorectal Cancer (mCRC) (2011) (3)
- [A Case of Leiomyosarcoma Arising from the Ovarian Vein Preoperatively Diagnosed with Radiological Imaging]. (2017) (3)
- Two phase III studies comparing 6 months of either mFOLFOX6 or XELOX with 3 months of the same regimen as adjuvant chemotherapy in patients with completely resected stage III colon cancer (ACHIEVE) or high-risk stage II colon cancer (ACHIEVE-2). (2014) (3)
- Analysis of esophagogastric cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase 1 trials (2015) (3)
- A multicentre phase I/II study of TAS-102 with nintedanib in patients with metastatic colorectal cancer refractory to standard therapies (N-TASK FORCE: EPOC1410); Phase I results (2016) (3)
- Final results of phase II study of S-1, oral leucovorin, oxaliplatin, and bevacizumab combination therapy (SOL+BV; SOLA) in metastatic colorectal cancer (mCRC). (2014) (3)
- Safety and efficacy of regorafenib in Japanese patients with metastatic colorectal cancer (mCRC) in clinical practice: Interim result from postmarketing surveillance (PMS). (2016) (3)
- [A Case of Late Onset Nivolumab-Induced Interstitial Nephritis in a Patient with Metastatic Renal Cell Carcinoma]. (2019) (3)
- A phase I/II study for panitumumab combined with TAS-102 in patients with RAS wild-type metastatic colorectal cancer (APOLLON study): Phase I results. (2017) (3)
- Minimal residual disease by circulating tumor DNA analysis for colorectal cancer patients receiving radical surgery: An initial report from CIRCULATE-Japan. (2021) (3)
- Prognostic factors for PFS in patients with advanced gastric cancer: Using the data from JCOG9912 study. (2011) (3)
- Concordance between PIK3CA mutations in endoscopic biopsy and surgically resected specimens of esophageal squamous cell carcinoma (2017) (3)
- 432P Pembrolizumab (pembro) for previously treated, microsatellite instability–high (MSI-H)/mismatch repair–deficient (dMMR) metastatic colorectal cancer (mCRC): Final analysis of KEYNOTE-164 (2021) (3)
- Efficacy and safety results in patients with impaired renal and hepatic function in the RECOURSE trial. (2016) (3)
- A phase II study of ziv-aflibercept (Z) + FOLFIRI in Japanese patients (pts) with metastatic colorectal cancer (mCRC). (2017) (3)
- O-026Combination of encorafenib and cetuximab with or without alpelisib in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC): phase 2 results (2016) (3)
- Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 years (2022) (3)
- Large-Scale Prospective Genome-Wide Association Study of Oxaliplatin in Stage II/III Colon Cancer and Neuropathy. (2021) (3)
- FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer. (2021) (3)
- A multicenter, multicohort, phase II study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing metastatic colorectal cancer. (2018) (3)
- 316O Genomic mechanisms of acquired resistance of patients (pts) with BRAF V600E-mutant (mt) metastatic colorectal cancer (mCRC) treated in the BEACON study (2022) (3)
- The role of the outpatient clinic in chemotherapy for patients with unresectable or recurrent gastric cancer. (2007) (3)
- Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study (2017) (3)
- The Detection of Urinary Podocytes from Drug-Induced Glomerular Thrombotic Microangiopathy in Advanced Cancer Patients. (2016) (3)
- Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer (2023) (3)
- Nintedanib (N) plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies: Health-related quality of life (HRQoL) results of the Phase III LUME-Colon 1 study. (2017) (3)
- Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor–Amplified Gastroesophageal Cancer: Retrospective Global Experience (2022) (3)
- VOLTAGE: Multicenter phase 1b/II study of nivolumab monotherapy and subsequent radical surgery after preoperative chemoradiotherapy with capecitabine in patients with locally advanced rectal cancer. (2018) (3)
- BRAF V600E potentially determines “Oncological Resectability” for “Technically Resectable” colorectal liver metastases (2021) (3)
- CanStem303C trial: A Phase 3 Study of napabucasin (NAPA) in combination with 5-fluorouracil (5-FU), leucovorin, and irinotecan (FOLFIRI) in adult patients (pts) with previously treated metastatic colorectal cancer (mCRC) - Trial in progress. (2018) (3)
- 434P Impact of molecular markers status on treatment effects comparing EGFR and VEGF monoclonal antibodies (mAbs) in untreated metastatic colorectal cancer (mCRC): Pooled individual patient data (IPD) analysis of randomized trials from the ARCAD database (2020) (3)
- The Nationwide Cancer Genome Screening Project for Gastrointestinal Cancer in Japan (GI-SCREEN): MSI-status and cancer-related genome alterations in advanced colorectal cancer (CRC)—GI-SCREEN 2013-01-CRC sub-study. (2016) (3)
- [Current Status and Future Perspectives of SCRUM-Japan]. (2017) (3)
- Clinicopathological features, efficacy of anti-EGFR therapy, and survival outcomes in patients with BRAF non-V600 mutated metastatic colorectal cancer. (2019) (3)
- Efficacy of pembrolizumab in microsatellite instability-high locally advanced cholangiocarcinoma: a case report (2021) (3)
- Early Tumor Shrinkage and Depth of Response in the Second-Line Treatment for KRAS exon2 Wild-Type Metastatic Colorectal Cancer: An Exploratory Analysis of the Randomized Phase 2 Trial Comparing Panitumumab and Bevacizumab in Combination with FOLFIRI (WJOG6210G) (2020) (2)
- 516PA Multicentre Phase I/II Study of TAS-102 with nintedanib in patients with metastatic colorectal cancer refractory to standard therapies (N-task force: EPOC1410) (2017) (2)
- 113TiP Prospective observational study monitoring circulating tumour DNA in resectable colorectal cancer patients undergoing radical surgery: GALAXY study in CIRCULATE-Japan (2020) (2)
- 610TiPLUME-COLON 1: DOUBLE-BLIND, RANDOMISED PHASE III STUDY OF NINTEDANIB (BIBF 1120) PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO PLUS BSC IN PATIENTS (PTS) WITH REFRACTORY COLORECTAL CANCER. (2014) (2)
- Trajectory for the Regulatory Approval of a Combination of Pertuzumab Plus Trastuzumab for Pre-treated HER2-positive Metastatic Colorectal Cancer Using Real-world Data. (2022) (2)
- Phase I study of AMG 479, a fully human monoclonal antibody against the type 1 insulin-like growth factor receptor (IGF-1R), in Japanese patients (pts) with advanced solid tumors. (2011) (2)
- Association of chemotherapy induced neutropenia at 1-month mark (CIN-1-month) and overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: A Cohort study. (2016) (2)
- ASO Author Reflections: The Moment That BRAF V600E Mutation Starts Evolving into “Precision Oncosurgery” in Colorectal Liver Metastases (2020) (2)
- 611TiPADJUVANT REGORAFENIB (REG) IN STAGE IV COLORECTAL CANCER (CRC) AFTER CURATIVE TREATMENT OF LIVER METASTASES: A PHASE III RANDOMIZED, PLACEBO (PBO)-CONTROLLED TRIAL (COAST). (2014) (2)
- Exploratory analysis of left- versus right-sided colorectal carcinoma in RAISE: A randomized, double-blind, phase 3 trial of ramucirumab (RAM) + FOLFIRI versus placebo (PBO) + FOLFIRI. (2017) (2)
- Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the CORRECT trial who had progression-free survival (PFS) longer than 4 months. (2015) (2)
- 506TiP Pembrolizumab plus lenvatinib versus standard of care for previously treated metastatic colorectal cancer (mCRC): Phase III LEAP-017 study (2021) (2)
- [Solitary Bladder Metastasis of Chromophobe Renal Cell Carcinoma: Report of a Case]. (2016) (2)
- Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study (2021) (2)
- A multicenter, multicohort, phase 2 study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing metastatic colorectal cancer - Trial in progress. (2018) (2)
- Solitary recurrence of prostate cancer surrounded by seminal vesicle/vas deferens‐like epithelium (2020) (2)
- Assessment of HER2 (ERBB2) amplification (HER2amp) using blood-based circulating tumor DNA (ctDNA) next generation sequencing (NGS) and correlation with tissue-based testing in metastatic colorectal cancer (mCRC). (2021) (2)
- bTMB-High Basket trial: A multicenter phase II trial of nivolumab monotherapy in patients with advanced gastrointestinal cancers with high blood tumor mutational burden (bTMB). (2019) (2)
- Impact of Adjuvant Radiotherapy and Reversibility of Neurogenic Bladder on Bladder Storage Function and Impact of Urethral Resistance on Bladder Emptying Function after Radical Hysterectomy (2017) (2)
- [Chemotherapy-naïve advanced pancreatic cancer with multiple liver metastases successfully treated by S-1 monotherapy--a case report]. (2006) (2)
- An international phase III randomized, non-inferiority trial comparing 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer: Compliance and safety of the phase III Japanese ACHIEVE trial. (2016) (2)
- Characteristics and clinical outcomes of patients with advanced gastric or gastroesophageal cancer treated in and out of randomized clinical trials of first-line immune checkpoint inhibitors (2022) (2)
- Microsatellite instability status in metastatic colorectal cancer and effect of immune checkpoint inhibitors on survival in MSI-high metastatic colorectal cancer (2019) (2)
- Phase I/II study of panitumumab (PANI) combined with trifluridine/tipiracil (FTD/TPI) in patients (pts) with previously treated RAS wild-type (wt) metastatic colorectal cancer (mCRC): Final results of APOLLON study. (2019) (2)
- Treatment outcome and recovery from peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer (JFMC41-1001-C2: JOIN Trial). (2017) (2)
- Analysis of hematologic adverse events (HeAEs) in trifluridine/tipiracil (FTD/TPI)-treated patients (pts) with or without renal/hepatic impairment (RI/HI): Pooled safety analyses from TAGS and RECOURSE. (2020) (2)
- Expert panel consensus recommendations on the use of circulating tumor DNA assays for patients with advanced solid tumors (2022) (2)
- Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study (2021) (2)
- DENEB: Development of new criteria for curability after local excision of pathological T1 colorectal cancer using liquid biopsy (2021) (2)
- Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis (2021) (2)
- Abstract 29: Phase I study of intravenous PI3K inhibitor BAY 80-6946 in Japanese subjects. (2013) (2)
- ACHIEVE-2 trial: A randomized phase III trial investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with high-risk stage II colon cancer (CC) (2019) (2)
- Integrated safety summary (ISS) for trifluridine/tipiracil (TAS-102) (2016) (2)
- 2123 Exposure-response (E-R) relationship of Ramucirumab (RAM) from a global, randomized, double-blind, Phase 3 study of patients (Pts) with advanced 2nd line colorectal cancer (2015) (2)
- EXPERT study: Randomized phase III trial of radical surgery and postoperative mFOLFOX6 versus perioperative mFOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases (CLMs). (2019) (2)
- ICGC-ARGO precision medicine: targeted therapy according to longitudinal assessment of tumour heterogeneity in colorectal cancer. (2022) (2)
- TiFFANY study: A multicenter phase II basket-type clinical trial to evaluate efficacy and safety of pan-FGFR inhibitor TAS-120 for advanced solid malignancies with FGFR alterations identified by circulating tumor DNA. (2019) (2)
- The predictive role of ERBB2 point mutations in metastatic colorectal cancer: A systematic review. (2022) (2)
- Translational research of VOLTAGE-A: Efficacy predictors of preoperative chemoradiotherapy and consolidation nivolumab in patients with both microsatellite stable and microsatellite instability-high locally advanced rectal cancer. (2021) (2)
- 209PCLINICAL VALIDATION OF A NOVEL MULTIPLEX KIT FOR ALL RAS MUTATIONS IN COLORECTAL CANCER: RESULTS OF RASKET(RAS KEY TESTING) PROSPECTIVE MULTICENTER STUDY. (2014) (2)
- Greater extent of blood‐tumor TCR repertoire overlap is associated with favorable clinical responses to PD‐1 blockade (2021) (2)
- The Nationwide Cancer Genome Screening Projects for Gastrointestinal Cancer in Japan (SCRUM-Japan GI-SCREEN): Efficient identification of actionable cancer genome alterations in advanced colorectal and non-colorectal gastrointestinal cancer (GI Screen 2013-01-CRC and 2015-01-Non CRC). (2015) (2)
- Tolerability study of adjuvant modified FOLFOX6 treatment in curatively resected stage II/III colon cancer (JFMC41-1001-C2: JOIN trial). (2014) (2)
- Characteristics of genomic alterations in circulating tumor DNA (ctDNA) in patients (Pts) with advanced gastrointestinal (GI) cancers in nationwide large-scale ctDNA screening:SCRUM-Japan Monstar-Screen. (2021) (2)
- COLOMATE challenge to overcome resistance in metastatic colorectal cancer. (2021) (2)
- SO-28 Effect of prior bevacizumab treatment in BRAF V600E-mutant metastatic colorectal cancer: Overall survival with encorafenib + cetuximab +/- binimetinib in BEACON CRC (2021) (2)
- Depressed-type (0-IIc) colorectal neoplasm in patients with family history of first-degree relatives with colorectal cancer: A cross-sectional study. (2006) (2)
- Relationship between serum HER2 level and histologic HER2 status in patients with advanced/recurrent gastric cancer. (2012) (2)
- [Predictive biomarkers for anti-EGFR antibodies]. (2012) (2)
- Prognostic factors in Japanese patients with advanced gastric cancer using the data from JCOG9912 study. (2011) (2)
- Translational research of voltage-A1: Efficacy predictors of preoperative chemoradiotherapy and subsequent nivolumab monotherapy in patients with microsatellite-stable locally advanced rectal cancer. (2020) (2)
- Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence: Results of an accent meta-analysis of seven studies. (2019) (2)
- LBA O-10 First-line panitumumab versus bevacizumab in combination with mFOLFOX6 for RAS wild-type metastatic colorectal cancer: PARADIGM trial results (2022) (2)
- BIG BANG study: A multicenter phase II study of the MEK inhibitor binimetinib + BRAF inhibitor encorafenib + anti-EGFR antibody cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer (EPOC 1703). (2018) (2)
- Clinicopathological features in metastatic colorectal cancer patients with KRAS wild type compared with codon 12 and codon 13 mutant: Results from a multicenter, cross-sectional study by the Japan study group of KRAS mutation in colorectal cancer. (2011) (2)
- Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study (2022) (2)
- Chronological improvement in precision oncology implementation in Japan (2021) (2)
- PLS. plenary session (2012) (2)
- FRESCO-2: A global phase III study of the efficacy and safety of fruquintinib in patients (pts) with metastatic colorectal cancer (mCRC). (2021) (2)
- 6121 POSTER Phase II Trial of Combination Therapy With Bevacizumab and S-1 in Elderly Patients With Unresectable or Recurrent Colorectal Cancer (BASIC) (2011) (2)
- Phase I/II study of S-1/LV plus oxaliplatin (SOL) for untreated metastatic colorectal cancer: Preliminary report of the phase I part (2008) (2)
- 6005 ORAL A Multicenter, Randomized, Double-blind, Phase II Study of TAS-102 (A) Plus Best Supportive Care (BSC) Versus Placebo (P) Plus BSC in Patients (pts) With Chemotherapy-refractory Metastatic Colorectal Cancer (mCRC) (2011) (2)
- Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first‐line treatment for metastatic colorectal cancer: Safety lead‐in results from the QUATTRO-II study (2021) (2)
- A phase II study of FOLFOXIRI with bevacizumab in untreated metastatic colorectal cancer patients: A UGT1A1 genotype and safety results (QUATTRO study). (2017) (2)
- Abstract B159: Phase I dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors. (2011) (2)
- O2–035SAFETY AND EFFICACY OF REGORAFENIB IN JAPANESE PATIENTS WITH METASTATIC COLORECTAL CANCER: A SUBGROUP ANALYSIS OF THE PHASE III CORRECT TRIAL (2013) (2)
- PD-010Association between chemotherapy-induced neutropenia at 1-month and overall survival in patients receiving TAS-102 for metastatic colorectal cancer (2016) (2)
- AJ-5SCRUM-Japan GI-SCREEN: The nationwide cancer genome screening projects for gastrointestinal cancer in Japan (2015) (2)
- Clinicopathological features of program death ligand-1 (PD-L1) expression with tumor-infiltrating lymphocytes (TILs), mismatch repair (MMR) and Epstein-Barr virus (EBV) status in a large cohort of gastric cancer. (2016) (2)
- Association of ERBB2 Copy Number and Gene Coalterations With Trastuzumab Efficacy and Resistance in Human Epidermal Growth Factor Receptor 2–Positive Esophagogastric and Gastric Cancer (2022) (2)
- D04Exposure-response (E-R) relationship of Ramucirumab (RAM) from a global, randomized, double-blind, Phase 3 study of patients (Pts) with advanced 2nd line colorectal cancer (2016) (2)
- LUME-Colon 1: A double-blind, randomized phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer (CRC) refractory to standard therapies. (2015) (2)
- Radiotherapy plus androgen deprivation therapy for prostate‐specific antigen persistence in lymph node–positive prostate cancer (2022) (2)
- Infusion-related reaction to ramucirumab plus FOLFIRI in patients with advanced colorectal cancer (2021) (2)
- The clinical presentation and favorable prognosis of patients with isolated metachronous brain metastasis from germ cell tumors. (2016) (2)
- LBA-7 Encorafenib plus cetuximab with or without binimetinib for BRAFV600E metastatic colorectal cancer (mCRC): Relationship between carcinoembryonic antigen (CEA) and clinical outcomes from BEACON CRC (2020) (2)
- Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC (2022) (2)
- JFMC51-1702-C7: Phase II study investigating efficacy and safety of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) in patients (pts) with metastatic colorectal cancer (mCRC) refractory or intolerant to standard chemotherapies (2019) (1)
- A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study (2022) (1)
- Clinicopathological factors influence diagnostic accuracy of clinical N staging for early gastric cancer. (2017) (1)
- Phase I/II study of oral fluoropyrimidine S-1 plus oral Leucovorin as first-line treatment for metastatic colorectal cancer (2007) (1)
- IS7-5NEW DRUG DEVELOPMENT FOR REFRACTORY METASTATIC COLORECTAL CANCER IN JAPAN (2014) (1)
- Clinical impact of renal impairment on the safety and efficacy of S-1 plus oxaliplatin in patients with advanced gastric cancer: a single institutional study. (2019) (1)
- [Efficacy of TAS-102]. (2015) (1)
- O-8 Final overall survival for the phase 3 KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer (2021) (1)
- Phase II KEYNOTE-164 study of pembrolizumab (pembro) monotherapy for patients (pts) with previously treated, mismatch repair-Deficient (dMMR) advanced colorectal cancer (CRC): Primary and Japan subgroup analyses. (2018) (1)
- Optimizing the treatment sequence from second-line to third-line therapy in patients with metastatic colorectal cancer: discussion. (2020) (1)
- Therapeutic effect of TAS-102 (A) in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard chemotherapy by the Köhne model (Km). (2012) (1)
- Rapid screening using pathomorphological interpretation to detect BRAFV600E mutation and microsatellite instability in colorectal cancer. (2022) (1)
- Concordance Between Recommendations From Multidisciplinary Molecular Tumor Boards and Central Consensus for Cancer Treatment in Japan (2022) (1)
- 438TiP MOUNTAINEER-03: Phase III study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer (trial in progress) (2022) (1)
- Randomized phase II study of regorafenib followed by cetuximab versus reverse sequence for wild-type KRAS metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and irinotecan (REVERCE). (2014) (1)
- Efficacy and safety of ramucirumab containing chemotherapy in patients with pretreated metastatic gastric neuroendocrine carcinoma. (2018) (1)
- 2113 Initial safety survey report from early post-marketing phase vigilance (EPPV) on TAS-102 for metastatic colorectal cancer (mCRC) (2015) (1)
- Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer (2019) (1)
- 6063 Phase I study of first-line sunitinib (SU) plus modified FOLFOX6 (mFOLFOX6) in Japanese patients (pts) with metastatic colorectal cancer (mCRC) (2009) (1)
- Reply: KRAS mutation in colorectal cancer metastases after adjuvant folfox for the primary (2012) (1)
- Effect on oxaliplatin-free interval for successful rechallenge of oxaliplatin in colorectal cancer patients who had experienced an oxaliplatin: Related hypersensitivity reaction. (2018) (1)
- Early-onset stage II/III colorectal adenocarcinoma in the IDEA database: Treatment adherence, toxicities, and outcomes from adjuvant fluoropyrimidine and oxaliplatin. (2021) (1)
- SO-25 A multicenter phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer: BRAVERY study (EPOC1701) (2020) (1)
- The nationwide cancer genome screening project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced esophageal cancer. (2018) (1)
- Effect of KRAS codon 12 or 13 mutations on survival with trifluridine/tipiracil in pretreated metastatic colorectal cancer: a meta-analysis (2022) (1)
- [A Case of Upper Urinary Tract MALT Lymphoma with Remarkable Thickness of Renal Pelvis and Ureter Wall]. (2018) (1)
- Trajectories of body weight change and survival among patients with mCRC treated with systemic therapy: Pooled analysis from the ARCAD database. (2022) (1)
- VOLTAGE-B study: Nivolumab monotherapy and subsequent curative surgery following preoperative chemoradiotherapy in patients with locally recurrent rectal cancer (LRRC) without previous radiotherapy. (2020) (1)
- ESMO-JSMO - Recent advances in the treatment of GI tract and liver cancer in the EU and Japan (2012) (1)
- PD-012Validation study of the 12-gene Recurrence Score (RS) in patients (pts) with stage II and III colon cancer (CC) without adjuvant chemotherapy; SUNRISE Study (2015) (1)
- Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: The NCCHE experience. (2015) (1)
- Clinicopathological and molecular biological characteristics of early-onset stage II/III colorectal adenocarcinoma: An analysis of 25 studies with 47,184 patients (pts) in the adjuvant colon cancer end points (ACCENT) database. (2020) (1)
- PD-017A multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE) (2015) (1)
- Trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer: results of a systematic review and meta-analysis (2023) (1)
- Clinical impact of BRAF V600E mutations in patients (pts) with resectable solitary colorectal liver metastases (CRLM) (2019) (1)
- Clinical activity of MAPK targeted therapies in patients with non-V600 BRAF mutant tumors (2022) (1)
- A multicenter phase I/II study of TAS-102 with nintedanib in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies (N-TASK FORCE): EPOC1410. (2016) (1)
- 626PPROGNOSTIC IMPACT OF HER2, EGFR, AND C-MET STATUS ON OVERALL SURVIVAL OF ADVANCED GASTRIC CANCER PATIENTS TREATED WITH STANDARD CHEMOTHERAPY WITHOUT TRASTUZUMAB IN A FIRST-LINE TREATMENT: A JAPANESE MULTICENTER COLLABORATIVE RETROSPECTIVE STUDY. (2014) (1)
- Abstract C6: Phase 1 study of conatumumab (AMG 655), a proapoptotic death receptor‐5 agonist antibody, in Japanese patients with advanced solid tumors (2009) (1)
- Survival impact on regorafenib (REG) and trifluridine/tipiracil hydrochloride (FTD/TPI) for patients with metastatic colorectal cancer: Single institutional experience. (2020) (1)
- [A Case of Renal Angiomyolipoma with Tumor Thrombus Invading the Inferior Vena Cava]. (2016) (1)
- Intestinal Perforation due to Neutropenic Enterocolitis in a Patient Treated with Bevacizumab for Ovarian Cancer (2020) (1)
- IS4. Trials in Progress (2012) (1)
- Prognostic impact of human epidermal growth factor-2 (HER2) status on overall survival (OS) of advanced gastric cancer (AGC) patients (pts) treated with standard chemotherapy without trastuzumab as a first-line treatment: A Japanese multicenter collaborative retrospective study. (2013) (1)
- Global BRAF testing practices in metastatic colorectal cancer. (2021) (1)
- 2107 Safety and efficacy on TAS-102 monotherapy in patients with metastatic colorectal cancer according to previous regorafenib (2015) (1)
- Gastrointestinal tumors, colorectal (2012) (1)
- Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: the NCCHE experience (2015) (1)
- 579PPrimary efficacy results and clinical impact of UGT1A1 genotype on safety from a Phase II study of FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer: The QUATTRO study (2017) (1)
- Case Report: A Case of Renal Cell Carcinoma Unclassified With Medullary Phenotype Exhibiting a Favorable Response to Combined Immune Checkpoint Blockade (2022) (1)
- The real-world data on microsatellite instability status in various unresectable or metastatic solid tumors. (2021) (1)
- Phase II Study Of S-1, Oral Leucovorin, Oxaliplatin and Bevacizumab Combination Therapy (SOL + BV; SOLA) in Patients with Unresectable Metastatic Colorectal Cancer (MCRC) (2012) (1)
- Abstract 27: A phase I study of MEK inhibitor BAY 86-9766 in Japanese patients with advanced or reflactory solid tumors. (2013) (1)
- Activity on Nationwide Cancer Genome Screening Project for Metastatic Colorectal Cancer in Japan; SCRUM-Japan GI-SCREEN (2019) (1)
- 8570 POSTER Phase II Study of Cetuximab With Concomitant-boost Radiotherapy (RT) in Japanese Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-SCCHN) (2011) (1)
- Pooled safety analysis from phase 3 studies of trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC) and metastatic colorectal cancer (mCRC). (2019) (1)
- Abstract B98: AUY922, a novel HSP90 inhibitor: Final results of a phase I dose escalation study in Japanese patients with advanced solid malignancies. (2011) (1)
- [Screening of Deep Vein Thrombosis Prior to Surgery Using D-dimer Testing and Venous Ultrasonography of Lower Extremities]. (2017) (1)
- Adjuvant Chemotherapy for Colon Cancer: Guidelines and Clinical Trials in Japan (2016) (1)
- Baseline absolute neutrophil counts (ANC) and survival in second-line metastatic colorectal cancer (mCRC) patients (pts). (2017) (1)
- Global BRAF testing practices in metastatic colorectal cancer (mCRC). (1)
- Japanese multicenter phase II study of CHOP followed by radiotherapy (RT) in stage I-II1 diffuse large B-cell lymphoma (DLBCL) of the stomach. (2004) (1)
- Phase I dose escalation (esc) trial of weekly intravenous (i.v.) BI 836845 in Japanese patients (pts) with advanced solid tumors (2016) (1)
- Non-biopsy technique for the differential diagnosis between non-neoplastic and neoplastic colonic lesions a prospective study (2000) (1)
- Microsatellite instability status in metastatic colorectal cancer and effect of immune checkpoint inhibitors on survival in MSI-high metastatic colorectal cancer. (2019) (1)
- Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials (2016) (1)
- O-0023 Phase 3 Correct Trial of Regorafenib in Metastatic Colorectal Cancer (mCRC) (2012) (1)
- O-21 METABEAM study: Combined analysis of concordance studies between liquid and tissue biopsies for RAS mutations in colorectal cancer patients with single metastatic sites (2020) (1)
- Exploratory evaluation of pharmacodynamic biomarkers and pharmacokinetics (PK) of ziv-aflibercept (Z) + FOLFIRI in a phase II study of Japanese patients (pts) with metastatic colorectal cancer (mCRC). (2017) (1)
- Current and Future Research Into the Mechanism of Action of Regorafenib. (2019) (1)
- Comprehensive Genomic Profiling of Circulating Tumor DNA in Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of a Real-World Healthcare Claims Database (2022) (1)
- Final results of a phase I trial of chemotherapy combination with docetaxel, cisplatin, and S-1 (TPS) in patients with locally advanced or recurrent metastatic head and neck cancer (HNC). (2007) (1)
- Clinical utility of quasimonomorphic variation range (QMVR) on the determination of microsatellite instability (MSI) status in Japanese patients (pts) with colorectal cancer (CRC): GI-SCREEN-CRC-MSI sub-study 01. (2017) (1)
- O2-5-3SAFETY AND EFFICACY OF REGORAFENIB IN NATIONAL CANCER CENTER HOSPITAL EAST (NCCHE) (2014) (1)
- SO-37 Evaluating age as a factor for survival and quality of life in patients with BRAF V600E-mutant metastatic colorectal cancer treated with encorafenib + cetuximab ± binimetinib: Subanalysis of BEACON CRC (2022) (1)
- Prophylactic use of oral dexamethasone (DEX) to alleviate fatigue during regorafenib (REG) treatment for patients with advanced colorectal cancer (aCRC). (2015) (1)
- A clinical validation study of RASKET-B: A multiple detection kit for RAS and BRAF gene mutations in colorectal cancer. (2017) (1)
- Future perspectives of chemotherapy for advanced gastric cancer (2009) (1)
- The TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab versus irinotecan and fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer. (2021) (1)
- Early clinical outcomes of anal squamous cell carcinoma treated with concurrent chemoradiotherapy with 5-Fluorouracil plus mitomycin C in Japanese patients: experience at a single institution. (2012) (1)
- Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer ; A JSMO - ESMO initiative. (2018) (1)
- SEAMARK: Randomized phase 2 study of pembrolizumab + encorafenib + cetuximab versus pembrolizumab alone for first-line treatment of BRAF V600E-mutant and microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC). (2022) (1)
- Oncology and public health (2012) (1)
- Clinical Outcome of Cetuximab for Metastatic Colorectal Cancer Patients Harboring Kras CODON61, Kras CODON146, Braf, Nras or PIK3CA Mutations (2012) (1)
- Biological difference of tumour mutational burden (TMB) and microsatellite instability (MSI) status in patients (pts) with somatic vs germline BRCA1/2-mutated advanced gastrointestinal (GI) cancers using cell-free DNA (cfDNA) sequencing analysis in the GOZILA study (2019) (1)
- Accelerating cancer omics and precision oncology in health care and research: a Lancet Oncology Commission. (2023) (1)
- Reply to `Comment on `Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) (2018) (1)
- Long-term effect of peripheral sensory neuropathy (PSN) of 3 or 6 months oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: ACHIEVE as part of the IDEA collaboration. (2018) (1)
- O-7 FOLFIRI ± napabucasin in patients with previously treated metastatic colorectal cancer: Overall survival results from the phase 3 CanStem303C study (2021) (1)
- Evaluation of outcomes over time (1998-2009) of patients (pts) with stage III colon cancer receiving adjuvant FOLFOX: Analysis of 7,230 patients from MOSAIC, C07, C08, N0147, AVANT, and PETACC8 trials in the ACCENT Database. (2018) (1)
- SUNRISE-DI study: decision impact of the 12-gene recurrence score (12-RS) assay on adjuvant chemotherapy recommendation for stage II and IIIA/B colon cancer. (2019) (1)
- 300MO Impact of dihydropyrimidine dehydrogenase (DPD) genotype on fluoropyrimidine-related toxicity in Asian population (2020) (1)
- Identification of site-specific genome alterations in metastatic colorectal cancer: Sub-study 003 of the SCRUM-Japan GI-SCREEN. (2019) (1)
- Plasma VEGF-D and PlGF levels according to prior use of biologics among metastatic colorectal cancer: Preliminary results from GI-SCREEN CRC-Ukit study. (2020) (1)
- Prognostic and predictive impact on FMS-like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer (2019) (1)
- The nationwide screening project on plasma angiogenesis-related mediators for treatment selection of optimal antiangiogenic inhibitors in metastatic colorectal cancer: GI-SCREEN CRC-Ukit. (2018) (1)
- BRAVERY study: A multicenter phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer (EPOC1701). (2018) (1)
- 2116 A multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE) (2015) (1)
- Pharmacokinetic and pharmacodynamic (PK/PD) analysis results from the phase 3 RECOURSE trial of trifluridine and tipiracil (TAS-102) versus placebo (pbo) in patients (pts) with refractory metastatic colorectal cancer (mCRC) (2016) (1)
- 80P Blood tumor mutational burden (bTMB) and efficacy of immune checkpoint inhibitors (ICIs) in advanced solid tumors: SCRUM-Japan MONSTAR-SCREEN (2021) (1)
- Vascular endothelial growth factor (VEGF)-D and clinical outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with second-line FOLFIRI plus bevacizumab (Bev): A biomarker study of the WJOG 6210G trial. (2020) (1)
- [Spindle cell sarcoma of the penis: a case report]. (2012) (1)
- Pembrolizumab (pembro) in Mismatch Repair-Deficient (dMMR) Advanced Colorectal Cancer (CRC): KEYNOTE-164 Japan Subgroup (2019) (1)
- Evaluating the clinical utility of universal screening to identify Lynch syndrome in stage III/III colorectal cancer patients: A prospective observational study in Japan. (2021) (1)
- [Endoscopic therapy for colorectal cancer]. (2003) (1)
- Integration of clinical information and molecular biology profile -Endeavor of SCRUM-Japan-. (2016) (1)
- 428 POSTER A phase I dose-escalation study of TAS-102, a novel oral functional antitumor nucleoside, administered twice daily to Japanese patients (pts) with advanced solid tumors (2008) (1)
- Clinicopathological features of program death ligand-1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer. (2017) (1)
- Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial. (2023) (1)
- Reply to the letter to the editor 'Neutropenia in metastatic colorectal cancer receiving trifluridine/tipiracil' by Giuseppe et al. (2020) (0)
- Nishi Memorial Award in Gastric Cancer (2008) (0)
- 477P Utilisation and predictors of genomic testing prior to first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) (2021) (0)
- [Clinical Effect of Nivolumab on Advanced Renal Cell Carcinoma with Peritoneal Metastasis]. (2019) (0)
- Cell-Free DNA to detect focal versus non-focal MET amplification in metastatic colorectal cancer patients: Combined analysis from Japan and the United States (2019) (0)
- 6109 POSTER Difference in Overall Survival in Colorectal Cancer Patients With the KRas P.G13D and Other KRas Mutations After the Failure of 5-fluorouracil, Oxaliplatin, and Irinotecan (2011) (0)
- Analysis of plasma angiogenesis factors on the efficacy of first-line (1L) chemotherapy (chemo) combined with biologics in RAS wild-type metastatic colorectal cancer (mCRC): Results from GI-SCREEN CRC Ukit study. (2022) (0)
- Abstract CT164: Circulating tumor DNA analysis for predictive and prognostic factors in patients with metastatic colorectal cancer: An exploratory analysis from the phase III PARADIGM study (2018) (0)
- Comparison of therapeutic features and oncologic outcome in patients with pN1 prostate cancer among robot-assisted, laparoscopic, or open radical prostatectomy (2022) (0)
- Using T stage to predict outcomes of adjuvant oxaliplatin (OX)-based chemotherapy (CT) in stage III colon cancer (CC): An ACCENT pooled analysis. (2022) (0)
- Reply by Authors. (2020) (0)
- Clinicopathological factors influence diagnostic accuracy of clinical N staging for early gastric cancer. (2017) (0)
- [A Case of Advanced Seminoma in a 79-Year-Old Man Successfully Treated with Etoposide and Cisplatin]. (2015) (0)
- SY32-2 Innovative challenge on circulating tumor DNA (ctDNA) – tailored adjuvant treatment: CIRCULATE-Japan (2021) (0)
- Safety for trifluridine/tipiracil (TAS-102) with bevacizumab combination in patients with refractory metastatic colorectal cancer in real-world clinical practice: The single-institutional experience. (2018) (0)
- Clinicopathological factors influence diagnostic accuracy of clinical N staging for early gastric cancer. (2017) (0)
- O3-16-6Clinical outcomes in 21 patients with gastrointestinal stromal tumor(GIST)treated in phase I trials: the NCCHE Experience (2015) (0)
- 2) Update on the Treatment for Colorectal Cancer (2012) (0)
- O3-6-6Gastrointestinal perforation and fistula formation in colorectal cancer patients during regorafenib treatment (2015) (0)
- Genetic polymorphisms of FCGR2A encoding Fcγ receptor IIa in a Japanese population and functional analysis of the L273P variant (2012) (0)
- Association of adverse events (AEs) with outcomes in early stage colon cancer (CC): An analysis of 10,695 CC patients from the ACCENT database. (2018) (0)
- 388P Early tumor shrinkage (ETS) and depth of response (DpR) analyses in metastatic colorectal cancer (mCRC) treated with first-line mFOLFOX6 plus panitumumab (PAN) or bevacizumab (BEV): Results from the phase III PARADIGM trial (2022) (0)
- Clinical significance of thymidine kinase 1 expression on TAS-102 treatment in RECOURSE phase III trial of TAS-102 versus placebo for metastatic colorectal cancer (2016) (0)
- Confirmative study of incidence of flat/depressed type in newly detected metachronows earty colorectal carcinomas (2001) (0)
- O1-13-3OUTCOMES IN 50 PATIENTS WITH ADVANCED GASTRIC CANCER TREATED IN PHASE I TRIALS: THE NCCHE EXPERIENCE (2014) (0)
- O18-3 Impact of plasma VEGF-A, VEGF-D and PlGF on the efficacy of 2nd-line chemotherapy combined with biologics in mCRC (2022) (0)
- Health-related quality of life (HRQoL) associated with fruquintinib in the global phase 3, placebo-controlled, double-blind FRESCO-2 study. (2023) (0)
- Efficacy and safety of nab-paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment for patients with advanced gastric cancer: A single institutional experience. (2020) (0)
- [Perspective of personalized (precise) cancer therapy based on predictive biomarkers]. (2014) (0)
- Clinicopathological characteristics and impact on efficacy of three versus six months of adjuvant chemotherapy in early-onset colon cancer: ACHIEVE and ACHIEVE-2 trials. (2021) (0)
- Safety and efficacy of trifluridine/tipiracil (TAS-102) plus bevacizumab in clinical practice for patients with refractory metastatic colorectal cancer. (2018) (0)
- O3-8-4Clinicopathological features of PD-L1 expression with MMR, EBV status and cancer genome alterations in MGC (2017) (0)
- 8539 Induction chemotherapy with docetaxel, cisplatin and S-1 (TPS) followed by proton therapy concurrent with cisplatin in the patients with T4 nasal cavity cancer (2009) (0)
- PS3-3 Post-operative genomic/epigenomic signatures of circulating tumor DNA and recurrence in colorectal cancer: COSMOS-CRC-01 (2022) (0)
- ISS1-1-1PF-05212384 + irinotecan Phase II study in metastatic colorectal cancer (mCRC): B2151005 Japanese lead-in-cohort (J-LIC) (2015) (0)
- Response to Letter to the Editor, 'Pharmacokinetics partly explains the relationship between CEA level and survival of colorectal cancer patients treated with ramucirumab,' by Ibrahim et al. (2018) (0)
- PD-13 Plasma RAS dynamics and efficacy of anti-EGFR rechallenge in patients with RAS/BRAF wild-type metastatic colorectal cancer: REMARRY and PURSUIT trials (2022) (0)
- Treatment and Survival Outcomes by Age Following Second-Line Therapy for Metastatic CRC (mCRC): Analysis of 13,149 Patients from the ARCAD Clinical Trials Program (2021) (0)
- The Mechanism of Action of Regorafenib in Colorectal Cancer: Q&A. (2019) (0)
- Tumor bulk as a prognostic biomarker and predictor of benefit from anti-EGFR therapy in patients with metastatic colorectal cancer: Analysis of 476 patients from the ARCAD Clinical Trials Program. (2021) (0)
- Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials (2016) (0)
- Molecular Residual Disease-guided Adjuvant Treatment in Resected Colorectal Cancer: Focus on CIRCULATE-Japan. (2022) (0)
- 1434TiP MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC): Trial in progress (2021) (0)
- Panitumumab beats bevacizumab in RAS wildtype left-sided metastatic colorectal cancer (2022) (0)
- PS1-2 Pembrolizumab vs chemotherapy for MSI-high/dMMR metastatic colorectal cancer: Asia subgroup of phase 3 KEYNOTE-177 (2021) (0)
- 2297 Clinical features of exceptional responders with unresectable and metastatic gastric cancers by palliative chemotherapy: A long follow-up (2015) (0)
- A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) refractory to standard chemotherapy: APOLLON study. (2018) (0)
- Age, gender, and performance status effects on efficacy of 3 versus 6 months of adjuvant oxaliplatin and fluoropyrimidine chemotherapy for stage III colon cancer: Phase III ACHIEVE trial as part of the IDEA collaboration. (2018) (0)
- Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study. (2022) (0)
- ISY-17-5Final survival results of a multicenter phase I/II study of TAS-102 with bevacizumab for mCRC (C-TASK FORCE) (2016) (0)
- 2158 The Nationwide Cancer Genome Screening Project for Gastrointestinal Cancer in Japan (GI-SCREEN): Simultaneous identification of KRAS, NRAS, BRAF, and PIK3CA mutation in advanced colorectal cancer (aCRC) (GI-SCREEN 2013-01) (2015) (0)
- 112P Pembrolizumab vs chemotherapy in patients with microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: Asia subgroup results of the phase III KEYNOTE-177 study (2020) (0)
- SY13-3 SCRUM-Japan adaptive platform trials to accelerate precision oncology innovations (2022) (0)
- Mucosa-associated lymphoid tissue lymphoma of the urinary bladder (2012) (0)
- Evaluating longitudinal toxicity of cetuximab in patients with metastatic colorectal cancer (mCRC): A pooled analysis from 1,302 patients in the ARCAD database. (2021) (0)
- ICGC-ARGO precision medicine: an update on targeted therapy based on longitudinal analysis of tumour heterogeneity and evolution in colorectal cancer. (2023) (0)
- Correction to: The initial assessment of expert panel performance in core hospitals for cancer genomic medicine in Japan (2021) (0)
- The Nationwide Cancer Genome Screening Project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced non-colorectal (Non-CRC) gastrointestinal cancer. (2016) (0)
- PS3-2 Genomic characterization of circulating tumor DNA in advanced genitourinary cancer patients SCRUM-Japan MONSTAR SCREEN (2021) (0)
- A novel and simple KRAS mutation detection method, FRET-Based Preferential Homoduplex Formation Assay (f-PHFA): Results from a multicenter, clinical evaluation trial. (2012) (0)
- Latest Advance and Future Perspective for the Treatment of Metastatic Colorectal Cancer (mCRC) (2019) (0)
- Outcome of Endoscopic Resection for Early Invasive Colorectal Cancer Based on the Tumor Recurrence (2005) (0)
- 415P Prognostic effect of postoperative serum carcinoembryonic antigen (CEA) combined with T4 versus T3 tumors in patients with high-risk stage 2 colon cancer: ACHIEVE-2 phase III randomized clinical trial (2020) (0)
- ESMO-JSMO Joint Symposium: Recent advances in the treatment of GI tract and liver cancer in the EU and Japan (2012) (0)
- A multiplexed NGS solution to evaluate potential tumor immune response and objectively stratify tumors by histopathology from FFPE samples. (2016) (0)
- Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy (2019) (0)
- Patient-specific meta-analysis of 12-gene colon cancer recurrence score validation studies for recurrence risk assessment after surgery with or without 5FU and oxaliplatin. (2022) (0)
- Quattro-II study: A multicenter randomized phase II study comparing capoxiri plus bevacizumab with FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer as the first-line treatment. (2020) (0)
- 401MO OS and long-term DFS with 3- vs. 6-month adjuvant oxaliplatin and fluoropyrimidine-based therapy for stage III colon cancer patients: A randomized phase III ACHIEVE trial (2020) (0)
- Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies (2020) (0)
- Comprehensive genomic profiling of circulating cell-free DNA (cfDNA) distinguishes focal amplification (amp) from aneuploidy among MET amps in diverse advanced cancer types. (2019) (0)
- Pembrolizumab in Asian patients with microsatellite‐instability‐high/mismatch‐repair‐deficient colorectal cancer (2022) (0)
- Future direction of the treatment for mCRC: Asian perspective. (2017) (0)
- 2328 Outcomes in 44 Patients with metastatic esophageal squamous cell carcinoma treated in phase 1 trials: the NCCHE Experience (2015) (0)
- A Randomized, Double-Blind, Phase (PH) III Study of Folfiri Plus Ramucirumab (RAM) or Placebo (PL) in Patients (Patients) with Metastatic Colorectal Carcinoma (MCRC) Progressed During or Following 1st-Line Therapy with Bevacizumab (BEV), Oxaliplatin (OXALI), and a Fluoropyrimidine (FP) (RAISE) (NCT0 (2012) (0)
- Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials (2022) (0)
- 2405 Comprehensive biomarker analyses in esophageal squamous cell carcinoma (2015) (0)
- Reply by Authors. (2019) (0)
- Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer (2020) (0)
- Mismatch repair-deficient or other molecular subtypes and efficacy of chemotherapy for advanced gastric cancer (2019) (0)
- Association of hypersensitivity reactions to oxaliplatin with cumulative dose of oxaliplatin. (2011) (0)
- 461PSAFETY, PHARMACOKINETICS (PK) AND EFFICACY OF CYCLIN-DEPENDENT KINASE (CDK) 4 AND 6 INHIBITOR, PALBOCICLIB (PD-0332991): RESULTS FROM A PHASE 1 STUDY IN JAPANESE PATIENTS (PTS). (2014) (0)
- Tumor response and survival outcomes of salvage concurrent chemoradiotherapy with three-dimensional conformal radiotherapy and 5-fluorouracil/platinum-based chemotherapy for postoperative locoregional recurrence of esophageal squamous cell carcinoma (2022) (0)
- Rapidly Progressive Bladder Cancer Diagnosed because of Spontaneous Bladder Rupture (2022) (0)
- 465 Detection of somatic mutations and gene amplification using Oncomine Cancer Research Panel with biopsy samples from patients with advanced gastric cancer (2015) (0)
- Abstract 3280: Phase 1 study of AMG 386, an anti-angiogenic Fc fusion protein targeting angiopoietin-1 and -2, in Japanese patients with advanced solid tumors (2011) (0)
- Incidence and risk factors for venous thromboembolism, bleeding, and death in colorectal cancer (Cancer‐VTE Registry) (2022) (0)
- Non-surgical treatment for localized gastric mucosa-associated lymphoid tissue (MALT) lymphoma: Preliminary results of a multicenter prospective study in Japan. (2004) (0)
- O7-3 Pembrolizumab vs chemotherapy in MSI-H / dMMR metastatic colorectal cancer: KEYNOTE-177 final analysis Asia subgroup (2022) (0)
- MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer—Trial in progress. (2023) (0)
- SO-19 Biomarker analysis using plasma angiogenesis factors in the TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab as second-line treatment for metastatic colorectal cancer (2022) (0)
- Statistical Consideration of Biases in Progression-Free Survival (PFS) Resulting from Differences in Imaging Schedules (2012) (0)
- SO-22 Clinical classification-based evaluation of adjuvant therapy with oxaliplatin in stage II colon cancer (2022) (0)
- Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study (2016) (0)
- Quality of life in patients with clean intermittent catheterization is similar to patients with spontaneous voiding in long term after radical hysterectomy (2019) (0)
- Genomic alterations after EGFR blockade in patients with RAS wild-type metastatic colorectal cancer: Combined tissue and blood-based analysis from SCRUM-Japan GI-SCREEN and GOZILA. (2019) (0)
- Profiling plasma angiogenesis factors after use of biologics in metastatic colorectal cancer (mCRC): Update results from GI-SCREEN CRC Ukit study. (2021) (0)
- 6050 Clinical features of interstitial lung disease induced by FOLFOX or FOLFIRI for colorectal cancer (2009) (0)
- P25-4 Efficacy predictors of preoperative CRT and consolidation nivolumab in patients with locally advanced rectal cancer (2021) (0)
- Clinicopathological features of microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) in Japanese patients. (2016) (0)
- Olaparib with or without bevacizumab or bevacizumab and 5-fluorouracil in advanced colorectal cancer: Phase III LYNK-003. (2021) (0)
- Multi-omics characterization of left-right colorectal cancer. (2021) (0)
- Interim analysis results of gut microbiota in patients with unresectable cholangiopancreatic cancer: SCRUM-Japan MONSTAR-SCREEN. (2023) (0)
- A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites (2018) (0)
- Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant (2023) (0)
- Molecular landscape and prognostic value of HER2 low-expression on metastatic colorectal cancer. (2020) (0)
- [Conversion therapy for colorectal cancer]. (2011) (0)
- 84MO A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01 (2020) (0)
- Characteristics of patients (pts) and prognostic factors across treatment lines (TL) in metastatic colorectal cancer (mCRC): An analysis from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. (2021) (0)
- [Clinical significance and the handling of KRAS testing on metastatic colorectal cancer]. (2011) (0)
- Abstract B29: Feasibility of amplicon sequencing using a pan-cancer gene panel with pre-treatment biopsy samples of (Japanese) patients with advanced solid tumors: Analyses of Biopsy Samples for Cancer Genomics (ABC) study. (2013) (0)
- Ensemble study: A multicenter, randomized, phase III trial to test the superiority of consolidation irinotecan, capecitabine and oxaliplatin vs capecitabine and oxaliplatin following short course radiotherapy as total neoadjuvant therapy in patients with locally advanced rectal cancer. (2023) (0)
- [Incidence and Risk Assessment of Tumor Lysis Syndrome in Patients with Advanced Germ Cell Cancer]. (2016) (0)
- What and how will the Risk Based Approach to Monitoring change? Survey of RBM in medical institutions (2021) (0)
- Efficacy of Targeted Trials and Signaling Pathway Landscape in Advanced Gastrointestinal Cancers From SCRUM-Japan GI-SCREEN: A Nationwide Genomic Profiling Program. (2023) (0)
- [MSI Status in Colorectal Cancer]. (2018) (0)
- O-010An international phase III randomized, non-inferiority trial comparing 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer: compliance and safety of the phase III Japanese ACHIEVE trial (2016) (0)
- MO42-6 The clinical and molecular landscape of focal MET-amplified metastatic colorectal cancer patients (2022) (0)
- Relationship between the immune microenvironment of different locations in a primary tumour and clinical outcomes of oesophageal squamous cell carcinoma (2019) (0)
- Survival outcomes and functional results of VOLTAGE-A: Preoperative chemoradiotherapy (CRT) and consolidation nivolumab (nivo) in patients (pts) with both microsatellite stable (MSS) and microsatellite instability–high (MSI-H) locally advanced rectal cancer (LARC). (2023) (0)
- Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial (2023) (0)
- Predictive factor of hyperprogressive disease during nivolumab in patients with advanced gastric cancer. (2018) (0)
- 342P Comparison of 0.25 mg versus 0.75 mg of palonosetron in combination with aprepitant and dexamethasone for prevention of chemotherapy-induced nausea and vomiting following cisplatin-containing chemotherapy in patients with esophageal cancer (2020) (0)
- Poor association between dihydropyrimidine dehydrogenase ( DPYD ) genotype and fluoropyrimidine‐induced toxicity in an Asian population (2022) (0)
- 2108 Subgroup analysis by KRAS status in RAISE: A randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression during or following first-line combination therapy with bevaci (2015) (0)
- Discovery of a potential predictive marker for eribulin treatment and novel target genes in BRAF V600E mutant metastatic colorectal cancer using an AI-driven RNA-seq analysis platform: Translational research of the BRAVERY study (EPOC1701). (2021) (0)
- Evaluation of ALK Fusion Newly Identified in Colon Cancer by a Comprehensive Genomic Analysis. (2019) (0)
- Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer (2022) (0)
- 407P Long-term effect of peripheral sensory neuropathy (PSN) of 3 or 6 months oxaliplatin-based adjuvant chemotherapy for high-risk stage II colon cancer: ACHIEVE-2 as part of the IDEA collaboration (2020) (0)
- Baseline creatinine clearance as an indicator of severe adverse events associated with oxaliplatin-based adjuvant chemotherapy in patients with stage III colon cancer: Safety analysis of the phase III Japanese ACHIEVE trial. (2017) (0)
- The COLOMATE Platform: An Indispensable Initiative Promoting True Precision Oncology Prioritized for Patients With Cancer-From "MAYBE" to "MUST BE". (2021) (0)
- Correction (2014) (0)
- Abstract 2935: Preclinical efficacy of the p70S6K/AKT dual inhibitor M2698 in combination with trastuzumab in models of gastric cancer (2018) (0)
- Clinical impact of renal impairment on safety in elderly colon cancer patients receiving capecitabine plus oxaliplatin as adjuvant therapy; multicenter post-marketing surveillance study. (2017) (0)
- Application of the RTOG recursive partitioning analysis classification to brain metastases from colorectal cancer (2007) (0)
- PD44-01 NOT A STRAIGHTFORWARD RELATION BETWEEN ESTIMATED DAILY SODIUM INTAKE AND NOCTURIA: THE NAGAHAMA STUDY (2020) (0)
- BAYONET trial: A multicenter phase II trial of staged combination with encorafenib + binimetinib + cetuximab following encorafenib + cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer. (2023) (0)
- SUNRISE-DI Study: Decision Impact of the 12-Gene RS Assay on Adjuvant Chemotherapy for Stage II and IIIA/B Colon Cancer (2019) (0)
- ' s response to reviews Title : Construction of possible integrated predictive index based on EGFR and ANXA 3 polymorphisms for chemotherapy response in fluoropyrimidine-treated Japanese gastric cancer patients using a bioinformatic method (2015) (0)
- Clinical and molecular features of responders to PD-1 blockade for patients with microsatellite instability high or mismatch repair deficient advanced gastrointestinal tumors. (2020) (0)
- Comparative sequence analysis between primary colorectal cancer, metastasis and recurrent metastasis after adjuvant FOLFOX chemotherapy (2016) (0)
- A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer (2015) (0)
- Phase 1B Study of a Novel Oral Ppar-Gamma Agonist, Efatutazone in Combination with Folfiri in Japanese Patients with Metastatic Colorectal Cancer who Failed the First-Line Therapy (2012) (0)
- Negative hyperselection of patients with RAS wild-type metastatic colorectal cancer for panitumumab: A biomarker study of the phase III PARADIGM trial. (2023) (0)
- 46MO FRESCO-2: A global / multiregional phase III clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with metastatic colorectal cancer (2022) (0)
- Impact of high-risk features on disease-free survival (DFS) in patients (pts) with high-risk stage II colon cancer (CC) in ACHIEVE-2 trial as part of the IDEA collaboration. (2020) (0)
- 567PClinical utility of quasi-monomorphic variation range (QMVR) on the determination of microsatellite instability (MSI) status in patients (pts) with colorectal cancer (CRC): GI-SCREEN-CRC-MSI sub-study 01 (2017) (0)
- OS1. gastric cancer (2012) (0)
- [A Case of Pelvic Unicentric Castleman Disease Treated by Preoperative Transcatheter Arterial Embolization and Tumor Complete Resection with Combined Lower Abdominal and Posterior Approach]. (2021) (0)
- Post-Marketing Survey of Panitumumab in Japanese Patients with Unresectable Colorectal Cancer: Interim Report of 3,005 Patients (2012) (0)
- ISS1-1-3Safety and efficacy on TAS-102 monotherapy in clinical practice in patients with metastatic colorectal cancer (mCRC) (2015) (0)
- APOLLON study: a phase I/II study for the safety and efficacy of panitumumab in combination with TAS-102 for patients with RAS wild-type metastatic colorectal cancer refractory to standard chemotherapy (2016) (0)
- Real-world outcome analysis of patients with advanced gastric and gastroesophageal adenocarcinoma with HER2-low expression treated with first-line therapy. (2023) (0)
- O9-1 Updated analysis of circulating tumor DNA in advanced genitourinary cancers: SCRUM-Japan MONSTAR SCREEN Project (2022) (0)
- Outcomes over time (1998-2009) of stage II colon cancer patients (pts) receiving adjuvant FOLFOX: Pooled analysis of 1,122 pts in the ACCENT database. (2018) (0)
- Genomic Landscape of Primary Tumor Site and Clinical Outcome for Patients with Metastatic Colorectal Cancer Receiving Standard-of-Care Chemotherapy (2022) (0)
- Survival outcomes following salvage abdominoperineal resection for recurrent and persistent anal squamous cell carcinoma (2023) (0)
- Expression of PD-L1 and PD-L2 in colorectal cancer (CRC): A post-hoc integrated analysis of SCRUM-Japan GI-SCREEN CRC. (2021) (0)
- 617P Genomic profiling of circulating tumor DNA in advanced genitourinary cancer patients: SCRUM-Japan MONSTAR SCREEN Nationwide Cancer Genome Screening Project (2021) (0)
- The Essentials of Multiomics (2022) (0)
- IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation (2022) (0)
- Adding Ramucirumab To Second-Line Irinotecan, 5-Fluorouracil and Folinic Acid (Folfiri) Treatment for Metastatic Colorectal Carcinoma (Mcrc): Resource Utilization Data from Raise, A Global, Randomized, Double-Blind, Multicenter Phase 3 Study (2017) (0)
- Identification of an optimal circulating tumor DNA (ctDNA) shedding threshold to detect actionable driver mutations in colorectal and pancreatic adenocarcinoma. (2022) (0)
- Phase 1 trial of OCV-C02, a peptide vaccine for metastatic colorectal cancer patients refractory to all standard chemotherapies. (2017) (0)
- Superficially elevated colonic adenoma changed to undetectable configuration on ordinary endoscopy during treatment with preferential cyclooxygenase-2 inhibitor (2003) (0)
- Fecal microbiota in patients with a stoma decreases anaerobic bacteria and alters taxonomic and functional diversities (2022) (0)
- An investigator-initiated phase II trial of a PARP inhibitor niraparib monotherapy for patients with pre-treated, BRCA-mutated, unresectable/recurrent biliary tract, pancreatic, and other gastrointestinal cancers (NIR-B trial). (2022) (0)
- A multicentre, prospective clinical evaluation study for analyzing RAS mutational status utilizing plasma circulating tumor DNA in patients with metastatic colorectal cancer. (2018) (0)
- 1705P HER2 intratumoral genetic and non-genetic heterogeneity in metastatic colorectal cancer (2022) (0)
- An open-label, phase II study of patritumab deruxtecan (HER3-DXd, U3-1402) in patients (pts) with previously treated advanced/metastatic colorectal cancer (CRC). (2021) (0)
- O2-8-1CLINICOPATHOLOGICAL FEATURES OF KRAS, NRAS, BRAF AND PIK3CA MUTATIONS IN JAPANESE PATIENTS WITH MCRC (2014) (0)
- Activity on the Nationwide Cancer Genome Screening Project for Gastrointestinal Cancer in Japan; SCRUM-Japan GI-SCREEN. (2017) (0)
- Use of regorafenib before re-challenging with chemotherapy-based regimens in patients with metastatic colorectal cancer: mechanistic rationale. (2020) (0)
- 421P Upfront chemotherapy vs. surgery for very low lying locally advanced rectal cancer without preoperative chemoradiation: The NAIR phase II/III trial (2020) (0)
- Feasibility of classical secondary hormonal therapies prior to docetaxel therapy in Japanese patients with castration-resistant prostate cancer: Multicenter retrospective study (2016) (0)
- 1597 Prognosis of leptomeningeal metastasis diagnosed by magnetic resonance imaging in 329 patients with advanced solid tumors (2015) (0)
- Multicenter phase Ib/II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study) - Trial in progress. (2018) (0)
- BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy for BRAFV600E metastatic colorectal cancer (mCRC). (2023) (0)
- [109th Scientific Meeting of the Japanese Society of Internal Medicine: symposium: 1. Recent treatments and progress in malignant tumors--chemotherapy and molecular targeting agents. Antibody therapy; 1) Update on the treatment for colorectal cancer]. (2012) (0)
- Dual inhibition of BET and mutant BRAF in BRAF-mutant colon cancer cells suppresses oncogenic pathways and synergistically inhibits their growth (2016) (0)
- Diagnostics and treatment for HER2+ mG&CRC: Learning outcomes of GetSMART. (2023) (0)
- MO38-2 Safety and pharmacokinetics (PK) of tusamitamab ravtansine (tusa) in Japanese patients (pts) with advanced solid tumors (2022) (0)
- 1142 POSTER Clinical Significance of Macrodissection in Two Different KRAS Tests for Colorectal Cancer: Results From a Multi-center Clinical Trial (2011) (0)
- Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE study (2021) (0)
- [A Retrospective Study of Lymph Node Dissection for Renal Cell Carcinoma]. (2022) (0)
- Survival outcome in HER2-amplified metastatic colorectal cancer (mCRC). (2018) (0)
- TRUSTY: A randomized multicenter phase II/III study of trifluridine/tipiracil and bevacizumab versus irinotecan, fluoropyrimidine, and bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy. (2018) (0)
- SL-1 Activity on Nationwide Cancer Genome Screening Project for Advanced Solid Tumors; SCRUM-Japan GI-/MONSTAR-SCREEN (2020) (0)
- Construction of possible integrated predictive index based on EGFR and ANXA3 polymorphisms for chemotherapy response in fluoropyrimidine-treated Japanese gastric cancer patients using a bioinformatic method (2015) (0)
- 463P Impact of plasma angiogenesis factors on the efficacy of 2nd-line chemotherapy combined with biologics in metastatic colorectal cancer (mCRC): Early efficacy results from GI-SCREEN CRC Ukit study (2021) (0)
- NOTCH gene alterations in metastatic colorectal cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN) (2022) (0)
- Association of postoperative serum carcinoembryonic antigen (CEA) with disease-free survival in patients with stage III colon cancer: ACHIEVE phase III randomized clinical trial. (2020) (0)
- 180P Clinical outcome of anal squamous cell carcinoma treated with chemoradiotherapy with 5-fluorouracil plus mitomycin C (2016) (0)
- Multidisciplinary Treatment of Liver Metastasis from Colorectal Cancer to Create Novel Evidences (2019) (0)
- ISY-17-2UGT1A1 genotype as an indicator of neutropenia for FOLFOXIRI with bevacizumab in patients with mCRC (QUATTRO study) (2016) (0)
- Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials (2022) (0)
- 432P Toxicity and efficacy of 1st line cetuximab (cetux)-based therapy in RAS wildtype (WT) older patients (pts) with metastatic colorectal cancer (mCRC): A pooled analysis from 1,274 pts in the ARCAD database (2020) (0)
- Author's response to reviews Title:Clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer Authors: (2015) (0)
- PD-029Baseline carcinoembryonic antigen (CEA) as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma (mCRC) phase 3 trial (2016) (0)
- Impact of learning program on treatment recommendations by molecular tumor boards and an artificial intelligence-based annotation system: A prospective study. (2022) (0)
- Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer (2023) (0)
- [Two cases of KRAS wild-type unresectable or recurrent colorectal cancer effectively treated by cetuximab after progression of prior chemotherapy]. (2009) (0)
- Atypical RAS Mutations in Metastatic Colorectal Cancer (2019) (0)
- Nationwide cancer genome screening project utilizing circulating tumor DNA analysis for advanced gastrointestinal cancer. (2018) (0)
- O18-1 One-year incidence of venous thromboembolism in colorectal cancer patients in the Cancer-VTE Registry (2022) (0)
- Phase Ib/II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study): Phase Ib results. (2018) (0)
- Utility of circulating tumor DNA (ctDNA) versus tumor tissue genotyping for enrollment of patients with metastatic colorectal cancer (mCRC) to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA combined analysis. (2020) (0)
- RET rearrangements may arise following anti-EGFR therapy in advanced colorectal cancer. (2018) (0)
- Bevacizumab in first-line therapy in lung metastases of colorectal cancer: An ARCAD pooled analysis. (2023) (0)
- P-18 REMARRY and PURSUIT trials: Liquid biopsy-guided re-challenge of anti-EGFR monoclonal antibody for patients with RAS/BRAF V600E wild-type metastatic colorectal cancer (2020) (0)
- Safety and efficacy of irinotecan administered after nivolumab for advanced gastric cancer (2019) (0)
- A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer (2019) (0)
- SO-14 The prognostic impact of KRAS G12C mutation in patients with metastatic colorectal cancer: A multicenter retrospective observational study (2021) (0)
- Clinicopathological differences between metachronous and synchronous multiple colorectal carcinomas (2000) (0)
- Efficacy of Radiotherapy to Primary Tumor After Nivolumab Treatment in Patients with Advanced Gastric Cancer (2019) (0)
- 565P Whole-exome sequencing of matched germline and plasma cell-free DNA portrays the somatic mutation landscape of refractory metastatic colorectal cancer and identifies mutated KDR/VEGFR2 as new cause of therapy resistance Sequencingtodetectcancergenomealterationsinadvancedcolorectalcancer(aCRC),c (2017) (0)
- O12-1 A novel gene-prediction model, virtual sequencing with deep learning to predict gene alterations in colorectal cancer (2021) (0)
- Comprehensive analysis of Japanese nationwide cohort data of particle beam therapy for pulmonary, liver and lymph node oligometastases: particle beam therapy versus high-precision X-ray radiotherapy. (2023) (0)
- Japanese multicenter phase II study of CHOP followed by radiotherapy (RT) in stage I-II1 diffuse large B-cell lymphoma (DLBCL) of the stomach (2004) (0)
- A phase I study of EMD 525797, a novel humanized monoclonal antibody to human integrin alpha v, in Japanese patients with solid tumor. (2017) (0)
- 317MO Efficacy of oxaliplatin-based adjuvant chemotherapy in older patients with stage III colon cancer: An ACCENT/IDEA pooled analysis of 12 trials (2022) (0)
- P2-5-22LUME-Colon 1: a randomized phase III study of nintedanib vs placebo in patients with advanced colorectal cancer (2015) (0)
- PD-008Adding ramucirumab to second-line irinotecan, 5-fluorouracil and folinic acid (FOLFIRI) treatment for metastatic colorectal carcinoma (mCRC): resource utilization data from RAISE, a global, randomized, double-blind, multicenter phase 3 study (2016) (0)
- O4-3 Utility of an artificial intelligence-curation system, QA Commons, for clinical sequencing: SCRUM-Japan MONSTAR-SCREEN (2021) (0)
- 182PClinical implementation of the universal tumor screening with the mismatch repair (MMR) proteins on decision impact of adjuvant chemotherapy in patients with resected stage II/III colorectal cancer (CRC) (2017) (0)
- New diagnostic method based on color imaging using endoscopic spectroscopy system (ESS) for colorectal neoplasms (2000) (0)
- Abstract CT523: An open-label, multicenter, phase 1b/2 Study of E7386 (Wnt/β-catenin pathway inhibitor) + pembrolizumab in patients with pretreated advanced solid tumors (2022) (0)
- O-16 Relative impact of T4 and N2 on the efficacy of 3 versus 6 months of adjuvant CAPOX for high-risk stage II and stage III colon cancer: ACHIEVE and ACHIEVE-2 trials (2020) (0)
- Distributions of FcγRIIa-131 and FcγRIIIa-158 polymorphisms and clinical response to cetuximab in Japanese patients with metastatic colorectal cancer (mCRC). (2011) (0)
- AJS-5 Forefront challenge in the SCRUM-Japan utilizing Artificial Intelligence (AI) – Virtual Sequencing (VSQ) and QA Commons (QAC) projects and beyond (2021) (0)
- Aflibercept with FOLFIRI in Japanese patients with metastatic colorectal cancer: results of a post-marketing surveillance (2022) (0)
- Concordance between PIK3CA mutations in endoscopic biopsy and surgically resected specimens of esophageal squamous cell carcinoma (2017) (0)
- Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database. (2022) (0)
- Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164. (2023) (0)
- Antitumor effect of cationic liposome incorporating keto-mycolic acid from Mycobacterium bovis bacillus Calmette-Guérin in mouse model. (2018) (0)
- 3430 Clinical outcomes in 21 patients with gastrointestinal stromal tumor (GIST) treated in phase I trials: The NCCHE Experience (2015) (0)
- Quadruplet regimen with capecitabine, irinotecan, oxaliplatin, and bevacizumab in chemo-naive patients with metastatic colorectal cancer: Results from the safety lead-in of QUATTRO-II study. (2021) (0)
- ISY-18-2Latest Advance to Clinical Development and Future Perspective for RAS/BRAF-mutated Metastatic Colorectal Cancer (2016) (0)
- ASO Author Reflections: Circulating Tumor DNA (ctDNA) as a Potentially Practice-Changing Innovation to Evolve “Precision Onco-Surgery” in Resectable Colorectal Liver Metastases (2021) (0)
- TRIDENTE trial: A phase II study of rechallenge with encorafenib, binimetinib, and cetuximab in patients with RAS wild-type/BRAF V600E–mutant metastatic colorectal cancer. (2023) (0)
- Systemic transduction of p16INK4a antitumor peptide inhibits lung metastasis of the MBT-2 bladder tumor cell line in mice. (2018) (0)
- [Chemotherapeutic agents and electrolyte imbalance]. (2015) (0)
- 1429 POSTER FCGRIIa-131 and FCGRIIIa-158 Polymorphisms – Distribution and Clinical Outcomes of Cetuximab-based Chemotherapy in Japanese Patients With Metastatic Colorectal Cancer (mCRC) (2011) (0)
- REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer (2021) (0)
- ICGC-ARGO precision medicine: an update on familial matters in pancreatic cancer. (2022) (0)
- TAS-102: more than an antimetabolite (2012) (0)
- [Diagnostic Accuracy of Transperineal MRI-Ultrasound Fusion Biopsy at the Introduction Period]. (2022) (0)
- ISY-17-3Subgroup analysis in RAISE: a phase III study of FOLFIRI + ramucirumab or placebo in patients with advanced mCRC (2016) (0)
- Abstract 2208: Detection of somatic mutations and gene amplifications using amplicon sequencing with biopsy samples from patients with advanced gastric cancer (2014) (0)
- Abstract 139: M2698, a novel dual inhibitor of p70S6K and Akt: preclinical efficacy in gastric cancer (2017) (0)
- Prospective multicenter study of the impact of the 12-gene assay recurrence score on adjuvant chemotherapy treatment recommendations for stage II/III colon cancer in the post-IDEA era: SUNRISE-Decision Impact study. (2018) (0)
- 349P Analysis of plasma angiogenesis factors on the efficacy of 2nd-line (2L) chemotherapy (chemo) combined with angiogenesis inhibitors (AIs) in metastatic colorectal cancer (mCRC): Results from GI-SCREEN CRC Ukit study (2022) (0)
- AGENT: An open-label phase III study of arfolitixorin versus leucovorin in modified FOLFOX-6 for first-line treatment of metastatic colorectal cancer. (2020) (0)
- [Complete Remission of Metastatic Renal Cell Carcinoma with Invasion of the Duodenum and Pancreas after Treatment with Nivolumab Plus Ipilimumab Followed by Axitinib and Surgery : A Case Report]. (2021) (0)
- Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer: an early post-marketing phase vigilance study (2022) (0)
- The comprehensive analysis of relationship between gut microbiome and treatment outcome of androgen deprivation therapy (ADT)-based treatment in patients with metastatic castration-sensitive and -resistant prostate cancer. (2023) (0)
- Authors & Collaborators _ RAISE study (2015) (0)
- Efficacy and Safety of Brazilian Green Propolis in Biochemically Recurrent Prostate Cancer after Radical Prostatectomy: A Single-Arm Phase II Study (2022) (0)
- Simultaneous identification of 36 mutations in KRAS codons 61and 146, BRAF, NRAS, and PIK3CAin a single reaction by multiplex assay kit (2013) (0)
- Abstract 2813: Clinical impact of immune microenvironment according to intratumoral locations of esophageal squamous cell carcinoma (2019) (0)
- 436TiP COLSTAR: Randomized, open-label, multicentre, phase III study comparing futuximab/modotuximab plus trifluridine/tipiracil to trifluridine/tipiracil in KRAS/NRAS and BRAF wild type (wt) metastatic colorectal cancer (mCRC) previously treated with both standard and anti-EGFR treatment (2022) (0)
- GL-2 Clinical recommendations on the diagnosis and use of TRK inhibitors in adult and pediatric patients with NTRK fusion-positive advanced solid tumors (2021) (0)
- Rationale and Design for the LUME-Colon 1 Study: A Randomized, Double-blind, Placebo-controlled Phase III Trial of Nintedanib plus Best Supportive Care (BSC) versus Placebo plus BSC in Patients with Advanced Colorectal Cancer Refractory to Standard Treatment (2015) (0)
- 323P Five-year efficacy and safety in a randomized phase III trial investigating duration of adjuvant oxaliplatin-based therapy (3- vs. 6-months) for patients with high-risk stage II colon cancer: ACHIEVE-2 trial (2022) (0)
- Patient-specific meta-analysis of 3 validation studies of the 12-gene colon cancer recurrence score assay for recurrence risk assessment after surgery with or without 5FU and oxaliplatin. (2021) (0)
- Trajectories of body weight change and survival among mCRC patients treated with systemic therapy: Pooled analysis from the ARCAD database. (2022) (0)
- Detection of presumed germline pathogenic variants of hereditary breast cancer predisposition genes in circulating tumor DNA: SCRUM-Japan MONSTAR-SCREEN. (2022) (0)
- Significance of chemotherapy-free interval and tumor regression grade in patients with recurrent esophageal squamous cell carcinoma receiving chemotherapy with fluorouracil and platinum after esophagectomy following preoperative chemotherapy (2021) (0)
- 60MO Gut microbiota and efficacy of immune-checkpoint inhibitors (ICIs) in patients (pts) with advanced solid tumor: SCRUM-Japan MONSTAR-SCREEN (2021) (0)
- PD-013Final survival results of a multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer patients refractory to standard therapies (C-TASK FORCE). (2016) (0)
- RAS status in circulating-tumor DNA (ctDNA) and outcomes during rechallenge treatments with anti-EGFR antibodies in metastatic colorectal cancer (mCRC). (2020) (0)
- Clinicopathological and molecular characteristics of early-onset stage III colon adenocarcinoma: An analysis of 25 studies with 35,713 patients in the Adjuvant Colon Cancer End Points (ACCENT) database. (2021) (0)
- Retrospective comparison between Nivolumab and Irinotecan for advanced gastric cancer (2019) (0)
- Final report of post-marketing survey of panitumumab in Japanese patients with unresectable advanced or recurrent colorectal cancer. (2013) (0)
- Optimizing the treatment sequence from second-line to third-line therapy in patients with metastatic colorectal cancer. (2020) (0)
- ISY-16-3Current status and future perspective in metastatic colorectal cancer: SCRUM-Japan GI-SCREEN project in Japan (2016) (0)
- P-80 A multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab and FOLFOXIRI plus bevacizumab as the first-line treatment for metastatic colorectal cancer: A safety analysis of the QUATTRO-II study (2022) (0)
- 442TiP A multicenter phase II clinical study evaluating the efficacy and safety of perioperative encorafenib, binimetinib plus cetuximab combination treatment in patients with surgically resectable BRAF V600E-mutant colorectal oligometastases (NEXUS) (2022) (0)
- P-45 An open-label, phase 2 study of patritumab deruxtecan in patients with previously treated advanced/metastatic colorectal cancer (2021) (0)
- 187PImpact of KRAS mutational status and primary tumor location on the efficacy of aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer: An exploratory analysis in a phase II study (2017) (0)
- The IDEA Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX Regimen for Patients with Stage III Colon Cancer: Current Status. (2014) (0)
- Abstract 1974: Clonal and subclonal mutational landscapes in circulating tumor DNA in metastatic colorectal cancer: An exploratory analysis from the phase III PARADIGM study (2020) (0)
- Comparison of therapeutic features and oncologic outcome in patients with pN1 prostate cancer among robot-assisted, laparoscopic, or open radical prostatectomy (2022) (0)
- Analysis of esophagogastric cancer patients enrolled in National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP)-sponsored phase I trials. (2015) (0)
- DJS-4 ARCAD-Asia Initiative: Leveraging yesterday's data for tomorrow (2022) (0)
- 6107 A pitfall of KRAS sequencing using a small amount of DNA extracted from formalin-fixed paraffin-embedded (FFPE) colorectal cancer tissues (2009) (0)
- SCRUM-Japan genesis virtual sequencing (VSQ) project: A novel algorithm combining deep learning (DL) with pathological diagnostics to enable the prediction of BRAF mutations and microsatellite instability (MSI) in advanced colorectal cancer (CRC). (2021) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Takayuki Yoshino?
Takayuki Yoshino is affiliated with the following schools:
